Podcasts about Pennington Biomedical Research Center

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comThis week on the podcast, Mikki speaks to Dr. James Dorling, a researcher whose work challenges many of the traditional assumptions around energy expenditure, weight loss, and personalised nutrition.Dr. Dorling's research spans multiple large-scale studies, including the E-MECHANIC trial, which revealed that traditional metabolic equations often overestimate energy burn—particularly in certain populations. His work also highlights differences in how men and women, and people of different ethnicities, respond to exercise in terms of energy expenditure, raising important questions about the accuracy of fitness trackers and calorie calculations.In this conversation, Mikki and James explore why some people seem to hit a weight-loss plateau despite regular exercise, how compensatory mechanisms might be working against fat loss goals, and what practical strategies can help break through these barriers. They also dive into findings from the CALERIE™ study, where unexpected predictors of weight loss—like sexual satisfaction—emerged, and discuss the potential for machine learning to improve personalised weight-loss strategies.Beyond metabolism, they tackle the hype around DNA-based nutrition plans and the reality of individual variability in weight loss outcomes.Dr. James Dorling is a lecturer in Human Nutrition at the University of Glasgow, with a research focus on the impact of nutrition and physical activity interventions on obesity, metabolic health, and aging biomarkers. His work explores appetite regulation, eating behaviours, and how these factors change in response to lifestyle interventions.Dr. Dorling completed his undergraduate degree in Sport and Exercise Science at the University of Bath before earning his PhD from Loughborough University, where he investigated the effects of acute exercise and obesity-related genetic factors on appetite and appetite-related hormones. He then continued his research as a postdoctoral fellow at the Pennington Biomedical Research Center, studying the influence of calorie restriction and exercise on weight regulation, aging, and metabolic adaptations.Dr. Dorling's work has been featured in leading scientific publications and podcasts, where he discusses the intersection of metabolism, exercise, and behaviour change. His research challenges conventional wisdom around weight loss and aims to refine personalised strategies for improving health outcomes.For more on his work, visit his profile at the University of Glasgow: https://www.gla.ac.uk/schools/medicine/staff/jamesdorling/  Curranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

When Louisianans heard that snow was coming to our state, many were skeptical. But yesterday, a rare winter storm hit the Bayou State, with the blizzard causing highways, airports and schools to close down.Meteorologist Dan Holiday discusses the record-breaking weather and what this says about a changing climate. A medical study is underway in Baton Rouge that could help determine whether a common diabetes drug could be used to stop muscle weakness associated with cancer treatment.While the drug isn't new, its effectiveness in cancer patients is still being tested. Justin Brown, associate professor and director of the Cancer Metabolism Program at Pennington Biomedical Research Center, is the director of this study. He joins us for more.  On Feb. 9, New Orleans will host the Super Bowl for the 11th time, tied with Miami for the most hosted by any city. As we get closer to the 59th annual event, we thought we would take a look at the Super Bowls of years past and hear about some of the most iconic games in New Orleans.Mark Cave, senior historian with the Historic New Orleans Collection walks us through the biggest games, the best performances, and the two blackouts – one for the media and one for the lights. __Today's episode of Louisiana Considered was hosted by Adam Vos. Our managing producer is Alana Schrieber. We get production support from Garrett Pittman and our assistant producer Aubry Procell.You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App and wherever you get your podcasts.Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!

Did you know that specific nutrients can help aid our immune system in preventing and treating the symptoms of cold, flu and Covid 19?  Join Food Sleuth Radio host and Registered Dietitian, Melinda Hemmelgarn for her conversation with Jacob Mey, PhD, RD,  Registered Dietitian and nutrition researcher at the Pennington Biomedical Research Center, as they delve into the best diet and nutrition approaches to support our immune system through the cold and flu season and beyond. For resources from the Pennington Biomedical Research Center see: https://www.pbrc.edu/training-and-education/community-health-resources/Related Websites: The Role of Nutrition in Mitigating the Effects of COVID-19 from Infection through PASC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9961621/#B72-nutrients-15-00866 Dietary Supplements for Immune Function and Infectious Diseases: https://ods.od.nih.gov/factsheets/ImmuneFunction-HealthProfessional/ Too much zinc and copper deficiency: https://thewaitingroom.karger.com/knowledge-transfer/zinc-oversupplementation-and-copper-deficiency/ Emerging Nutrition Approaches to Support the Mind and Muscle for Healthy Aging: file:///C:/Users/Dan/Downloads/rpn.2204022.pdf

Send us a textIn this compelling episode, we dive into a powerful conversation with Dr. Jenn Caldwell, Assistant Professor at the Pennington Biomedical Research Center and Director of the Public Health Genomics and Health Equity Laboratory at LSU. Dr. Caldwell unpacks her groundbreaking research on health equity, genetic testing, and community-driven solutions to tackle chronic illnesses disproportionately affecting marginalized communities. From exploring the ancestral roots of African Americans through the Gullah Geechee community to the transformative "Lincoln Gains Project," Dr. Caldwell sheds light on the intersection of genetics, lifestyle, and public health.We discuss the pressing challenges of systemic racism, the cultural significance of HBCUs, and practical tips for achieving healthier lifestyles despite socioeconomic barriers. Whether you're curious about the role of epigenetics, the importance of representation in research, or actionable ways to improve wellness in underserved communities, this episode offers an engaging blend of science, culture, and storytelling.This is a must-watch for socially conscious audiences, culturally engaged Millennials and Gen Xers, educators, and professionals who seek authentic narratives that inspire change. Join us for a thought-provoking journey into how genetics and culture shape our lives and communities. Don't forget to like, comment, and subscribe for more insightful discussions! #healthequity  #genetics  #BlackExcellence #hbcu  #wellnessjourney  #socialjustice  #notallhood-----------------------------------------------------------------------------------------------------Not All Hood (NAH) podcast takes a look at the lived experiences and identities of Black people in America. Infused with pop culture, music, and headlining news, the show addresses the evolution, exhilaration, and triumphs of being rooted in a myriad of versions of Black America. Hosted by Malcolm-Jamal Warner, Candace O.Kelley, and WeusiBaraka Executive Produced by Layne Fontes Produced by Kelly Brett Associate Producer Troy W. Harris, Jr.

Subscribe to our channel: https://www.youtube.com/@optispan Check out Cristal's page at USC: https://gero.usc.edu/faculty/cristal-m-hill-phd/ Matt recently attended the 52nd annual meeting of the American Aging Association in Madison, Wisconsin and met with several people doing fascinating work in or adjacent to the geroscience field. One of these was Cristal Hill. Cristal is an Assistant Professor of Gerontology at the University of Southern California Leonard Davis School of Gerontology, where she runs a lab focused on how dietary protein might affect adipose tissue (body fat) function, metabolic, and endocrine health during aging. Cristal received postdoctoral training at the Pennington Biomedical Research Center of Louisiana State University, a PhD in molecular biology from Southern Illinois University, and a B.S. in Animal Sciences from Tuskegee University. In this episode, Matt and Cristal discuss fibroblast growth factor 21 (FGF21), a hormone produced mainly in the liver that helps regulate metabolism and control how the body uses sugar and fat for energy. They also chat about FGF21's influence on food preferences, role in healthy aging and longevity, potential as an obesity treatment, and more, as well as the broader impact of protein restriction on health- and lifespan as we age. Some definitions: the term "wildtype" refers to the typical form of an organism or gene as it occurs in nature, and represents the standard or normal genetic makeup and phenotype against which mutants or genetically modified organisms are compared. A "knockout" is an organism in which a specific gene has been completely disabled or "knocked out" to study the gene's function by observing the differences between the knockout organism and a wildtype one. Finally, a "transgenic" organism is one that has had a gene or genes introduced into its DNA to give the organism new traits or abilities, such as resistance to diseases, or to study the effects of the introduced gene. DISCLAIMER: The information provided on the Optispan YouTube channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/

Subscribe to our channel: https://www.youtube.com/@optispan Matt recently attended the 52nd annual meeting of the American Aging Association in Madison, Wisconsin and met with several people doing fascinating work in or adjacent to the geroscience field. One of these was Cristal Hill. Cristal is an Assistant Professor of Gerontology at the University of Southern California Leonard Davis School of Gerontology, where she runs a lab focused on how dietary protein might affect adipose tissue (body fat) function, metabolic, and endocrine health during aging. Cristal received postdoctoral training at the Pennington Biomedical Research Center of Louisiana State University, a PhD in molecular biology from Southern Illinois University, and a B.S. in Animal Sciences from Tuskegee University. In this episode, Matt and Cristal discuss fibroblast growth factor 21 (FGF21), a hormone produced mainly in the liver that helps regulate metabolism and control how the body uses sugar and fat for energy. They also chat about FGF21's influence on food preferences, role in healthy aging and longevity, potential as an obesity treatment, and more, as well as the broader impact of protein restriction on health- and lifespan as we age. Some definitions: the term "wildtype" refers to the typical form of an organism or gene as it occurs in nature, and represents the standard or normal genetic makeup and phenotype against which mutants or genetically modified organisms are compared. A "knockout" is an organism in which a specific gene has been completely disabled or "knocked out" to study the gene's function by observing the differences between the knockout organism and a wildtype one. Finally, a "transgenic" organism is one that has had a gene or genes introduced into its DNA to give the organism new traits or abilities, such as resistance to diseases, or to study the effects of the introduced gene. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/

Dr. Katzmarzyk is Professor and Associate Executive Director for Population and Public Health Sciences at the Pennington Biomedical Research Center where he holds the Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes. Dr. Katzmarzyk is an internationally recognized leader in the field of physical activity and obesity, with a special emphasis on pediatrics and ethnic health disparities. He has over two decades of experience in conducting large clinical and population-based studies in children and adults. He has published his research in more than 580 scholarly journals and books, and has delivered over 210 invited lectures in 16 countries. In addition to his research, Dr. Katzmarzyk plays a leading role in national health advocacy initiatives. He chairs the Research Advisory Committee for the U.S. Report Card on Physical Activity for Children and Youth for the National Physical Activity Plan Alliance. He also recently served on the 2018 U.S. Physical Activity Guidelines Advisory Committee for the U.S. Department of Health and Human Services and the World Health Organization Guideline Development Group for the WHO 2020 Guidelines on Physical Activity and Sedentary Behavior in Youth, Adults and Older Adults. In 2019 and 2020, Dr. Katzmarzyk was recognized as a highly cited researcher by the Web of Science. _____________________ This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store, and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Join experts in obesity: Dr Robert Kushner (Professor of Medicine at Northwestern Feinberg School of Medicine and Director of the Center for Lifestyle Medicine at Northwestern Medicine in Chicago), Dr Eric Ravussin (Associate Executive Director at the Pennington Biomedical Research Center in Baton Rouge, Louisiana), and Dr Jeffrey Sicat, (Endocrinology Physician and Founder of  Virginia Weight and Wellness medical practice in Richmond, Virginia) as they discuss the science behind metabolic adaption and why this makes weight loss so difficult to maintain over time. The panel will also discuss the essential role healthcare professionals play by providing education and support to their patients with obesity and working with their patients to develop a personalized weight management plan.   This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.   Faculty Presenters:   Robert Kushner, MD Professor, Departments of Medicine and Medical Education Northwestern University Feinberg School of Medicine Chicago, IL Eric Ravussin, PhD Boyd Professor and Associate Executive Director- Clinical Science Pennington Biomedical Research Center Baton Rouge, LA Jeffrey Sicat, MD, FACE Founder and Medical Director Virginia Weight and Wellness Glen Allen, VA

Join experts in obesity: Dr Robert Kushner (Professor of Medicine at Northwestern Feinberg School of Medicine and Director of the Center for Lifestyle Medicine at Northwestern Medicine in Chicago), Dr Eric Ravussin (Associate Executive Director at the Pennington Biomedical Research Center in Baton Rouge, Louisiana), and Dr Jeffrey Sicat, (Endocrinology Physician and Founder of  Virginia Weight and Wellness medical practice in Richmond, Virginia) as they discuss the science behind metabolic adaption and why this makes weight loss so difficult to maintain over time. The panel will also discuss the essential role healthcare professionals play by providing education and support to their patients with obesity and working with their patients to develop a personalized weight management plan.   This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.   Faculty Presenters:   Robert Kushner, MD Professor, Departments of Medicine and Medical Education Northwestern University Feinberg School of Medicine Chicago, IL Eric Ravussin, PhD Boyd Professor and Associate Executive Director- Clinical Science Pennington Biomedical Research Center Baton Rouge, LA Jeffrey Sicat, MD, FACE Founder and Medical Director Virginia Weight and Wellness Glen Allen, VA   Episode Contributors: Dr Robert Kushner, Dr Eric Ravussin, Dr Jeffrey Sicat

Much as we love to tout our fun loving lifestyle in south Louisiana, we have some of the worst health outcomes in the country – including the highest rates of cancer, heart disease, stroke, and infant mortality. On this edition of Out to Lunch, Jim Engster sits in for Stephanie and is joined by two lunch guests who both head up institutions in Baton Rouge's growing Health District. Beyond providing reactive medical care to these already existing health issues, John Kirwan, Rene Ragas and their respective institutions are focused on what causes these diseases in the first place and how to proactively keep our population healthier long term.   John Kirwan is Executive Director of Pennington Biomedical Research Center here in Baton Rouge, which is renowned the world over for its focus on diabetes and obesity. John himself is internationally renowned as an expert in diabetes and nutrition science with more than 30 years of research and teaching and a specialty in type 2 diabetes and how to potenitally cure it. John came to the center in 2018 from the famed Cleveland Clinic, and in the years since has generated more than $50M in research funding and spearheaded the opening of Pennington's obesity treatment center. John was a guest on Out to Lunch  back in the pandemic era, when we were meeting on zoom. A lot has happened since then and it is great to see John in person.  Rene Ragas is President and CEO of Woman's Hospital in Baton Rouge, the largest birthing hospital in the state. Since opening in 1968, Woman's has delivered nearly 400,000 babies and is reocngized for its Level 3 neonatal intensive care unit, expertise in mammography and breast and cancer care. What's perhaps less well known is the hospital's research capabilities, especially in cervical cancer, where Woman's has been a pioneer since the implementation of pap screening test used to detect this type of cancer. Rene joined the hospital in 2022. He has more than two decades of experience as a healthcare executive, most recently as north shore market president for the FMOL health system. Out to Lunch is recorded live over lunch at Mansurs On the Boulevard. During the recording of this show the power went out in parts of Baton Rouge but the medics and Jim soldiered on! You can find photos from this show at itsbatonrouge.la.See omnystudio.com/listener for privacy information.

Links: Go to episode page Subscribe to Premium Join the Sigma email list Go to our recommended resources About This Episode: Have you ever wondered how exercise affects our appetite and energy intake? While we know that single bouts of exercise can create a short-term energy deficit, do they also influence our hunger levels? And what about long-term exercise training? Could it modify our appetite in ways that help us better control our weight? Recent research suggests that exercise may indeed play a role in appetite regulation. Could exercise modify the subjective and homeostatic mediators of appetite in ways that enhance our feelings of fullness after a meal? One of the most fascinating aspects of this research is the variability in responses between individuals. Why do some people experience changes in appetite and energy intake after exercise, while others don't? Could factors like adiposity, sex, or habitual physical activity levels play a role? In this episode, Dr. James Dorling of the University of Glasgow helps us delve into the evidence surrounding how factors like adiposity, sex, and habitual physical activity modulate our responses to exercise in terms of appetite, energy intake, and appetite-related hormone responses. About The Guest: Dr. James Dorling is a lecturer in Human Nutrition at the University of Glasgow. Dr. Dorling's research is broadly focused on three areas: (1) the impact of nutrition and physical activity interventions on obesity-related endpoints and biomarkers of aging; (2) the regulators of appetite and eating behaviours; and (3) the changes in appetite and eating behaviours in response to health interventions. During his PhD, he studied the effects of acute exercise and obesity-related single nucleotide polymorphisms on appetite and appetite-related hormones. Following this, Dr. Dorling joined Pennington Biomedical Research Center where he worked as a postdoctoral researcher. His postdoctoral research principally focussed on the influence of calorie restriction and physical activity on weight, markers of aging, and eating behaviours.

The effects of oral contraceptives and hormonal intrauterine devices on strength and recovery across the menstrual cycle phases. BIO: Hannah Cabre is a registered dietitian and a postdoctoral fellow at Pennington Biomedical Research Center. Her research focuses on the effects female sex hormones across the lifespan on nutrition, health, and performance. Her current work seeks to evaluate the importance of skeletal muscle maintenance for long-term health during the menopause transition. 

In this special series on obesity, our host, Dr. Neil Skolnik, discusses the obesity epidemic with some of the foremost experts in the world. In Part 2 of the series, Dr. Skolnik is joined by Drs. Deborah Horn, Thomas Wadden, and Donna Ryan. Together, they discuss, in detail, approaches to obesity including lifestyle, medications and bariatric surgery. The Focus on Obesity series is a collaborative project of the American Diabetes Association and the American Academy of Family Physicians. The entire program will comprise a total of seven episodes: four episodes of Diabetes Core Update, which will cover topics of interest for family physicians, primary care clinicians, and other health care professionals; as well as three episodes of its sister podcast, Diabetes Day by Day, which will be tailored for people with overweight or obesity and their caregivers. The combined seven-episode program will be released between February and June 2024 and can be freely accessed at https://diabetesjournals.org/journals/pages/podcasts_obesity. Funding support for the “Focus on Obesity” series is jointly provided by Lilly and Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Thomas Wadden PhD,  is a Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. He is the former director of the Center for Weight and Eating Disorders at Penn.   Donna Ryan, MD Professor emeritus at the Pennington Biomedical Research Center in Baton Rouge, Louisiana. Deborah B. Horn, DO, MPH, Medical Director for the UT Center of Obesity Medicine and Metabolic Performance; Fellowship Program Director, Allison Family Foundation Fellowship in Clinical Obesity Medicine and Metabolism, McGovern Medical School Selected references:  STEP-1 Trial (Semaglutide) – Wilding J,  Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021; 384(11), 989-1002. DOI: 10.1056/NEJMoa2032183 SURMOUNT-1 Trial (Tirzepatide) - Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et. al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022; 387(3), 205-216. DOI: 10.1056/NEJMoa2206038 STEP – 4 Trial - Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021; 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224 SURMOUNT-4 Trial - Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945 Diabetes Prevention Program Trial:  Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393– 403  Look Ahead Trial: Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

Editor's Note: This was recorded prior to Wegovy being approved for cardiovascular disease. View the story here. This podcast episode discussed the impact of celebrity endorsements on trends in weight loss drugs like Ozempic, body image issues, and the role of pharmacists in educating patients on appropriate use of GLP-1 medications for weight management and chronic diseases. Experts Include:  Patricia Mars, MD, owner and medical director of Venus By Mars Cosmetic Surgery and La Paloma Surgery Center; Donna H. Ryan, MD, Professor Emerita at Pennington Biomedical Research Center; and Christina Madison, PharmD, FCCP, AAHIVP, the Public Health Pharmacist. Key Takeaways 1. Celebrities have long shaped cultural ideals around aesthetics and beauty through their own appearance trends. 2. Social media promotion of weight loss journeys using GLP-1 drugs like Ozempic by influencers increased public interest, but also risked unsafe practices without medical oversight. 3. While celebrity disclosure of personal experiences can boost awareness of obesity as a medical condition, it's important for endorsements to encourage safe and supervised use of pharmaceutical therapies. 4. Compounded versions of medications like semaglutide lack proper quality control and approval, posing potential dangers. 5. Pharmacists play a key role in educating patients on appropriate and regulated use of emerging weight loss therapies. References 1. Han SH, Safeek R, Ockerman K, et al. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthet Surg J. 2023;44(1):60-67. doi:10.1093/asj/sjad211 2. Arillotta D, Floresta G, Guirguis A, et al. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023;13(11):1503. Published 2023 Oct 24. doi:10.3390/brainsci13111503 3. Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci Rep. 2023;13(1):20998. Published 2023 Nov 28. doi:10.1038/s41598-023-48267-2

CME credits: 1.00 Valid until: 03-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/application-of-motivational-interviewing-and-shared-decision-making-techniques-in-obesity-management/16385/ Experts review best practices for the incorporation of motivational interviewing and shared decision-making strategies to improve the treatment of obesity. Tune in with Dr. Megan Adelman, Clinical Pharmacist of Family Medicine at Cleveland Clinic Akron General in Ohio, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Daniel Zalinov, Physician Assistant who specializes in Internal Medicine at Atrium Health in Charlotte, North Carolina. =

CME credits: 1.00 Valid until: 27-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/treating-obesity-as-a-chronic-disease/16389/ Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women's Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.=

Links: Subscribe to PREMIUM Go to episode page (with linked studies) Receive the weekly Sigma email newsletter Recommended resources About this Episode: The PROPEL (Promoting Successful Weight Loss in Primary Care in Louisiana) trial was a cluster-randomized weight loss trial, specifically tailored to address the pressing health concerns of an underserved population in Louisiana, where obesity rates have reached alarming levels. The core of the intervention comprises a pragmatic, high-intensity lifestyle-based obesity treatment program, thoughtfully designed to be integrated within primary care settings. Over a 24-month duration, this multi-component weight loss program is delivered by skilled health coaches who are embedded in primary care clinics, with the aim of instigating substantial and sustainable weight loss outcomes. In this study, 803 participants were enrolled, of whom 67% identified as Black and 84% as female, thereby ensuring a diverse representation. The research design randomized 18 clinics, allocating them equally into two groups: usual care and an Intensive Lifestyle Intervention (ILI). The usual care group continued to receive their customary primary care, serving as the benchmark against which the ILI's efficacy will be measured. In this episode we have the opportunity to delve deeper into the intricacies of the PROPEL trial and gain insights from one of its lead researchers, Dr. John Apolzan of the Pennington Biomedical Research Center.  

Join LaTangela as she chats with the team from Pennington Biomedical Research Center on the #TanLine We are faced with so many health disparities within our community, it is important to open the line of communication. Asking questions to lead us to the results we desire to see for ourselves, famiy and loved ones. Dr. Robert Newton, Jr. - Associate Professor, head of the Physical Activity and Ethnic Minority Health Laboratory at Pennington Biomedical Research Center Jasmine Butler - Community Outreach Coordinator Floyd Hodoh - Community Outreach Coordinator Mark your calendar and make plans to join us for the Senior Black American Healthfair Saturday, March 30, 2024 We are starting the conversation early, as it is just that important to have you join us! For more details contact - 228-763-2869 NEW MUSIC ALERT NEVER KNEW - LaTangela Fay NEW BOOK ALERT P.O.O.F. (Power Over Obstacles Forever) - LaTangela Fay Sherman ************************************************************************************ THE LATANGELA SHOW TANTUNE RADIO -  WEMX- Baton Rouge, La. Mon-Fri 10a.m.-3p.m.CST TV - WLFT - Baton Rouge, La. KGLA  - New Orleans, La. The Louisiana Film Channel YouTube - #LaTangelaFay Podcast - ALL digital platforms www.LaTangela.com See omnystudio.com/listener for privacy information.

An interview with Dr. Peter Katzmarzyk, Professor at the Pennington Biomedical Research Center at Louisiana State University.In terms of the actual infrastructure for physical activity, we do fairly well when we're stacked up against other countries. However, where we kind of fall down is on the actual behaviors themselves. So when we actually measure physical activity in the children or sedentary behavior, active transportation, it becomes apparent that we're not taking advantage of that physical activity infrastructure. And we're not really maximizing those opportunities. Dr. Peter KatzmarzykReport card historyComparing the U.S. with other countriesActive transportationBehind the scenes perspectiveTen indicatorsTaking action on youth physical inactivitySedentary behaviorCOVID-19 pandemicChronic and infectious disease and physical activityActive play and family and peersMoving the dial on youth physical inactivityhttps://www.movetolivemore.com/https://www.linkedin.com/company/move-to-live-more@MovetoLiveMore

This week on the Gaining Health podcast, we interview the Queen of Obesity Medicine herself, Dr. Donna Ryan! Dr. Ryan and Karli discuss how it was that Dr. Ryan became involved with many of the sentinel nutrition and obesity studies, how obesity management has progressed throughout the years, potential concerns with the newer antiobesity medications, and Dr. Ryan tackles some of the biggest questions about how to prevent the tsunami of obesity and obesity-related complications that will come our way unless we change course.Dr. Donna Ryan is professor emerita of Pennington Biomedical Research Center, a campus of Louisiana State University in Baton Rouge, where, until retirement, she directed clinical research for 22 years. Her own research includes participation on the teams that developed and executed studies such as Dietary Approaches to Stop Hypertension (DASH), Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost), Diabetes Prevention Program (DPP) and Action for Health in Diabetes (Look AHEAD). Dr. Ryan's continuing interests focus on the translation of effective weight management into primary care practices. She is the past president of The Obesity Society and has served as panel co-chair to revise the NIH-supported evidence-based Guidelines on the Evaluation and Management of Overweight and Obesity in Adults. Her scholarly activities include authorship of more than 200 original publications and 45 books, chapters and reviews, primarily in the field of obesity.Support the showThe Gaining Health Podcast will release a new episode monthly, every second Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer monthly and annual Memberships, which include live group coaching, a community forum to ask questions and post resources, pre-recorded Master Classes, digital resources inlcuding patient education materials and office forms, and much more! We also sell our popular Gaining Health products, including a book on developing an obesity management program, editable forms and templates, and patient education materials in our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

In today's episode, we interview Dr. Stephanie Compton, PhD, RD, a Postdoctoral Researcher at Pennington Biomedical Research Center, a Registered Dietician, a cancer metabolism expert, and sharing her information on Instagram @Steph.Compton.PhD. She shares nuanced nutrition and health information on social media. She got her Bachelors in Biology at Emory & Henry College then her Master of Science in Human Nutrition, Foods, and Exercise and Dietetics at Virginia Tech. She also got her PhD in Human Nutrition, Foods, and Exercise at Virginia Tech. Full shownotes can be found at: thePHmillennial.com/episode130Dr. Stephanie Compton, PhD, RD on Instagram: https://www.instagram.com/steph.compton.phd/?hl=enNutrition Lab PRO: https://thenutritionlabpro.mn.co/Join Community Health & Wellness Discord: https://www.thephmillennial.com/joinOmari on IG: https://www.instagram.com/thephmillennial Omari on LinkedIn: https://www.linkedin.com/in/omari-richins All ways to support The Public Health Millennial: https://thephmillennial.com/support/ Shop at The Public Health Store: https://thephmillennial.com/shop/Support the show

Videos: How Technology Is Negatively Affecting You (12:00) Stunning AI shows how it would kill 90%. w Elon Musk. (15:58) What's Coming Is WORSE Than A Recession” – Chamath Palihapitiya (15:03) Heather Mac Donald On How The Delusion of Diversity Destroys Our Common Humanity(11:02) Potatoes can be part of a healthy diet Louisiana State University, November 18, 2022 When we think of healthy vegetables, we don't think of potatoes, but we should. Potatoes have developed a reputation for causing weight gain and an increased risk for type 2 diabetes, and often find themselves on a list of foods to avoid, especially for individuals with insulin resistance. However, a new study from Pennington Biomedical Research Center at Louisiana State University, published in the Journal of Medicinal Food, says that potatoes actually did not increase that risk, are filled with key nutrients, and packed with health benefits. Candida Rebello, PhD, an assistant professor at Pennington Biomedical, said, “We demonstrated that contrary to common belief, potatoes do not negatively impact blood glucose levels. In fact, the individuals who participated in our study lost weight.” “People tend to eat the same weight of food regardless of calorie content in order to feel full,” Rebello explained. “By eating foods with a heavier weight that are low in calories, you can easily reduce the number of calories you consume. The key aspect of our study is that we did not reduce the portion size of meals but lowered their caloric content by including potatoes. Each participant's meal was tailored to their personalized caloric needs, yet by replacing some meat content with potato, participants found themselves fuller, quicker, and often did not even finish their meal. In effect, you can lose weight with little effort.” The study involved 36 participants between the ages of 18 and 60 who were overweight, had obesity, or insulin resistance. Insulin resistance refers to a health condition in which the body's cells do not respond well to insulin and glucose does not enter into the cells to make energy. Insulin resistance is linked to obesity, high blood pressure, high cholesterol, and type 2 diabetes Participants were fed precisely-controlled diets of widely available common foods including either beans, peas, and meat or fish, or white potatoes with meat or fish. Both diets were high in fruit and vegetable content and substituted an estimated 40% of typical meat consumption with either beans and peas or potatoes. Previous studies have shown that eating beans and peas improves blood glucose levels in individuals with newly diagnosed type 2 diabetes. To increase the dietary fiber component of the potatoes, they were boiled with the skin intact and then refrigerated between 12 and 24 hours. Potatoes were incorporated into the main lunch and dinner entrées, and served together with sides such as mashed potatoes, oven-roasted potato wedges, potato salad, and scalloped potatoes with lunch and dinner entrees. “We prepared the potatoes in a way that would maximize their fiber content. When we compared a diet with potatoes to a diet with beans and peas, we found them to be equal in terms of health benefits,” Rebello said. “People typically do not stick with a diet they don't like or isn't varied enough. The meal plans provided a variety of dishes, and we showed that a healthy eating plan can have varied options for individuals striving to eat healthy. In addition, potatoes are a fairly inexpensive vegetable to incorporate into a diet.” (NEXT) Celery Seed Extract Lowers High Blood Pressure in Human Study University of Chicago Medical Center, November 8, 2022 Drugs to lower blood pressure are among the most commonly prescribed medicines in the U.S. More than 678 million blood pressure prescriptions were filled in 2010. All of the current classes of blood pressure lowering drugs possess significant side effects.A recent study with a special extract of celery seed extract indicates that it may produce clinical results without producing the side effects that plague current drug treatment. Celery seed extract contains an important compound known as 3-n-butylphthalide, or 3nB for short, that is also responsible for the characteristic flavor and odor of celery. 3nB was discovered as the active component of celery in response to investigations by researchers seeking to explain some of the medicinal effects of celery, including the lowering of blood pressure and the relief of arthritis. 3nB first drew significant scientific attention when researchers identified it as the factor in celery responsible for the blood pressure lowering effect of celery. The research was prompted by one of the researcher's father, who after eating a quarter-pound of celery every day for one week observed his blood pressure dropped from 158 over 96 to a normal reading of 118 over 82. A recent human study evaluated the efficacy of a standardized extract of celery seed supplying 85 percent 3nB in 30 patients with mild to moderate hypertension. The dosage was 150 mg per day. The results showed a statistically significant decrease in both systolic (SBP) and diastolic blood pressure (DBP) compared to baseline measurements. The change at week six for the SBP was 8.2 mmHg and for the DBP was 8.5 mmHG. No side effects were reported. These results indicate that celery seed extract may produce the greatest blood pressure-lowering effects in natural products available on health food store shelves. A major advantage of celery extract over conventional drugs used in high blood pressure is that drugs like beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers tend to significantly lower the blood flow to the brain While this effect is helpful in reducing the likelihood of stroke, it often leaves patients taking these drugs feeling tired, depressed, dizzy, and forgetful. Celery extract on the other hand has actually been shown to not only help prevent stroke in animal studies, but also improve blood flow as well and act to protect the brain and enhance energy production with the brain. (NEXT) Exercise during pregnancy gives newborn brain development a head start University of Montreal, November 10, 2022 As little as 20 minutes of moderate exercise three times per week during pregnancy enhances the newborn child's brain development, according to researchers at the University of Montreal and its affiliated CHU Sainte-Justine children's hospital. This head-start could have an impact on the child's entire life. “Our research indicates that exercise during pregnancy enhances the newborn child's brain development,” explained Professor Dave Ellemberg, who led the study. “While animal studies have shown similar results, this is the first randomized controlled trial in humans to objectively measure the impact of exercise during pregnancy directly on the newborn's brain.We hope these results will guide public health interventions and research on brain plasticity. Most of all, we are optimistic that this will encourage women to change their health habits, given that the simple act of exercising during pregnancy could make a difference for their child's future.” Not so long ago, obstetricians would tell women to take it easy and rest during their pregnancy. Recently, the tides have turned and it is now commonly accepted that inactivity is actually a health concern. “While being sedentary increases the risks of suffering complications during pregnancy, being active can ease post-partum recovery, make pregnancy more comfortable and reduce the risk of obesity in the children,” Curier explained. “Given that exercise has been demonstrated to be beneficial for the adult's brain, we hypothesized that it could also be beneficial for the unborn child through the mother's actions.” To verify this, starting at the beginning of their second trimester, women were randomly assigned to an exercise group or a sedentary group. Women in the exercise group had to perform at least 20 minutes of cardiovascular exercise three times per week at a moderate intensity, which should lead to at least a slight shortness of breath. Women in the sedentary group did not exercise. The brain activity of the newborns was assessed between the ages of 8 to 12 days, by means of electroencephalography, which enables the recording of the electrical activity of the brain. “We used 124 soft electrodes placed on the infant's head and waited for the child to fall asleep on his or her mother's lap. We then measured auditory memory by means of the brain's unconscious response to repeated and novel sounds,” Labonté-LeMoyne said. “Our results show that the babies born from the mothers who were physically active have a more mature cerebral activation, suggesting that their brains developed more rapidly.” (NEXT) Keeping indoor humidity levels at a ‘sweet spot' may reduce the spread of COVID-19 Massachusetts Institute of Technology, November 14, 2022 We know proper indoor ventilation is key to reducing the spread of COVID-19. Now, a study by MIT researchers finds that indoor relative humidity may also influence transmission of the virus. Relative humidity is the amount of moisture in the air compared to the total moisture the air can hold at a given temperature before saturating and forming condensation. In a study appearing in the Journal of the Royal Society Interface, the MIT team reports that maintaining an indoor relative humidity between 40 and 60% is associated with relatively lower rates of COVID-19 infections and deaths, while indoor conditions outside this range are associated with worse COVID-19 outcomes. To put this into perspective, most people are comfortable between 30 and 50% relative humidity, and an airplane cabin is at around 20% relative humidity. The findings are based on the team's analysis of COVID-19 data combined with meteorological measurements from 121 countries, from January 2020 through August 2020. Their study suggests a strong connection between regional outbreaks and indoor relative humidity. In general, the researchers found that whenever a region experienced a rise in COVID-19 cases and deaths prevaccination, the estimated indoor relative humidity in that region, on average, was either lower than 40% or higher than 60% regardless of season. Nearly all regions in the study experienced fewer COVID-19 cases and deaths during periods when estimated indoor relative humidity was within a “sweet spot” between 40 and 60%. “There's potentially a protective effect of this intermediate indoor relative humidity,” suggests lead author Connor Verheyen, a Ph.D. student in medical engineering and medical physics in the Harvard-MIT Program in Health Sciences and Technology. “However, we find that maintaining an indoor relative humidity in that sweet spot—of 40 to 60%—is associated with reduced COVID-19 cases and deaths.”In all, they focused on 121 countries where COVID-19 outbreaks occurred. For each country, they also tracked the local COVID-19 related policies, such as isolation, quarantine, and testing measures, and their statistical association with COVID-19 outcomes. In warmer times, both outdoor and indoor relative humidity for each country was about the same, but they quickly diverged in colder times. While outdoor humidity remained around 50% throughout the year, indoor relative humidity for countries in the Northern and Southern Hemispheres dropped below 40% in their respective colder periods, when COVID-19 cases and deaths also spiked in these regions. (NEXT) Why Are Kids So Great at Learning? GABA Brown University, November 16, 2022 GABA is the abbreviation for the neurotransmitter γ-aminobutyric acid. In the study, published in the journal Current Biology, researchers explain GABA's crucial role in helping children process new information and prepare their brains to learn and store even more. “What we found is a rapid increase in GABA in children, associated with learning,” says lead study author Takeo Watanabe, a professor of cognitive and linguistic sciences at Brown University. The neurotransmitter GABA plays an important role in helping the brain consolidate new info, Watanabe says. It “stabilizes” the network so that subsequent learning doesn't override what was already there and defends knowledge against retrograde interference. Yet this kind of GABA inhibitory processing is not fully matured in children, he says. Kids have lower levels of GABA—it's why they have less inhibitory abilities and weaker impulse control than adults. So if GABA is necessary to set the brain up to learn consecutive items, and children have less GABA than adults, then how are children able to, as Watanabe puts it, “learn and learn and learn and learn?” Using an advanced imaging technique called functional MRS, they measured the concentration of GABA in early visual cortical areas before, during and after learning sessions. They then compared the concentrations between children (ages 8 to 11) and adults (ages 18 to 35). They found that before learning begins, the overall amount of GABA in children is indeed smaller than in adults, Watanabe says. However, the researchers found that children exhibited a rapid boost in GABA concentration in the second round of learning, while the concentration of GABA in adults did not change.The results of the experiments suggest that compared with adults, children exhibit more dynamic GABA-associated inhibitory processing, which more rapidly adapts to stabilize learning than in adults, the researchers conclude. (NEXT) Being comfortable with aging can benefit sex life University of Missouri, November 17, 2022 Researchers have long known that having a positive outlook can benefit a person's health.Now, a new study by the University of Missouri has found older adults who feel positively about aging have a healthier sex life—a finding that didn't surprise the researcher, who's been studying the benefits of the positive perceptions of aging.”We know positive perceptions of aging can be really beneficial, but when they are negative, they can be really detrimental. Negative perceptions of aging are linked to higher likelihood of cognitive decline, higher likelihood of cardiovascular disease and even shorter lifespans. We wanted to see how it would affect people's sexual relationships. As expected, thinking positively about the way you age can also lead to a healthy sex life.” “We found this relationship to be strong with both men and women,” Skoblow said. “With data from more than 1,100 couples, we were able to find that participants with a more positive perception of aging also had sex more frequently as well as increased satisfaction.” “It's possible that if people expect a steep physical decline as an inevitable part of aging, they could have anticipatory inhibitions. They stop enjoying themselves in the moment and could have less satisfying sexual encounters,” Skoblow said. “We also know that western cultures often have many youthful beauty ideals, so maybe people with more positive perceptions of aging don't buy into them as much, leading to a more satisfying sex life as their body begins to change.”

It's Friyay! And we are ready to celebrate Friendsgiving!  Today as we continue to celebrate our Trans community, how can you be a good Ally? Also, if you have a hard time falling asleep could cherry juice be the answer?  Special guest: Frank Greenway -Medical Director and Professor at Pennington Biomedical Research Center

In this episode of Run with Fitpage, we had one of the top researchers in the world - Dr. Claude Bouchard. Dr. Bouchard is a Professor and the John W. Barton, Sr. Endowed Chair in Genetics and Nutrition at Louisiana State University's Pennington Biomedical Research Center (PBRC), where he is also the Director of the Human Genomics Laboratory. Vikas and Dr. Bouchard talk all about obesity, and the role of genetics in this episode.Dr. Bouchard is known for his research on the role of genetics in obesity and in the process of adaptation to regular physical activity. He was president of the Obesity Society in 1991–92. Bouchard graduated from Laval University with a B.P.Ed degree in 1962. He received his M.Sc. in exercise physiology from the University of Oregon the following year before doing postgraduate work at the University of Cologne and the German Sport University Cologne in Germany for two years (1963–65). In 1977, he received his Ph.D. from the University of Texas at Austin, after which he completed his postdoc at the University of Montreal in the same year. In 1999, after teaching kinesiology at Laval University for over thirty years, he joined the faculty of the Pennington Biomedical Research Center, where he was the Executive Director and George A. Bray Chair in Nutrition until 2010.Dr. Bouchard has been a fellow of the Royal Academy of Medicine of Belgium since 1996. He became an Officer of the Order of Leopold II of Belgium in 1994, a member of the Order of Canada in 2001, and a Chevalier in the Ordre National du Quebec in 2005. In 2002, he received the Honor Award from the American College of Sports Medicine. He is a fellow of the American College of Sports Medicine, the American Society for Nutrition, the Obesity Society, the American Heart Association, and the American Association for the Advancement of Science. In 2016, the Louisiana State University (LSU) Board of Supervisors voted unanimously to award him a Boyd Professorship, the most prestigious title that can be awarded to professors at LSU.Vikas hosts this weekly podcast and enjoys nerding over-exercise physiology, nutrition, and endurance sport in general.  He aims to get people to get out and 'move'.  When he is not working, he is found running, almost always.  He can be found on nearly all social media channels but Instagram is preferred:)Reach out to Vikas:Instagram: @vikas_singhhLinkedIn: Vikas SinghTwitter: @vikashsingh1010

Dr. Westin and Dr. Justin C. Brown discuss how physical activity can improve disease-free and overall survival in colorectal cancer and its potential application across all cancer types.   TRANSCRIPT   The guest on this podcast episode has no disclosures to declare. Dr. Westin: Hello, everybody, and welcome to another episode of JCO After Hours, the podcast where we get in depth on recent manuscripts published in the Journal of Clinical Oncology. And it is my great pleasure today to tell you we're going to be talking about a really important manuscript: “Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 Alliance Study.” And this was published in the JCO on August 9th, 2022.   All participants in the podcast have no conflicts of interest.   And I am very excited to welcome the first author on this important paper, Dr. Justin C. Brown. He is the Director of the Cancer Metabolism Program and Assistant Professor in Cancer Energetics at the Pennington Biomedical Research Center at Louisiana State University.   Welcome, Dr. Brown. Thank you for being here. Dr. Justin C. Brown: Thanks so much for having me. Dr. Westin: So, this is some really important work, and I think we're starting to see more and more really objective data around the importance of physical activities. But before we get too far down the road, I do want to level set because this was a study in colon cancer. So, just because we have a really mixed audience, give us a quick bit of information about the standard treatment for colon cancer and where we are with survival outcomes. Dr. Justin C. Brown: Yeah. So, for most patients with early colon cancer, they'll get upfront surgery. And then a subset of patients who have high-risk features for recurrence, or have positive lymph nodes or tumor deposits, will get three or six months of chemotherapy. And outcomes have improved over time for this population, but there is still a lot of heterogeneity, in that, some patients do better than others. And you know, a lot of patients ask as they finish therapy or as they're starting therapy, "Are there things I can do that potentially could improve my outcomes?" And so, we think that this data will provide physicians with a lot of really important information regarding the benefits of physical activity during chemotherapy, as well as after therapy, for patients with stage three colon cancer. Dr. Westin: Okay, that's great. And so, again, continuing on that level-setting piece, before this study, what did we know about the impact of physical activity on outcomes in colon cancer? Dr. Justin C. Brown: So, we knew that there was some association between physical activity during chemotherapy and after chemotherapy with disease-free survival and overall survival. There have been studies that have linked those two things. There was some uncertainty about, what is the best exercise or physical activity prescription? And so, a lot of the current recommendations before this study basically said encourage patients to avoid sedentary behavior, encourage them to be as active as they can be, because some activity provides benefits over no activity. But for the patient who really wanted the specifics of how much should I be doing, when should I be doing it, what types of activities should I be doing, should I avoid certain things, the evidence was really absent. And so, what this study provides is a lot of important clarity for both physicians and patients about the types of activities that can maximize their disease-free survival and overall survival. Dr. Westin: I think that's so important because you're exactly right. We all have those patients that you give them a vague, and they're like, "No, I need instructions. I need to know how much time. I need to know what I'm doing." And it can be really frustrating because—I know personally, I'm like, "Well, this is what I do.” And I'm like, is that enough? I have no idea. So, this is really important work.   And before we get into the specifics of the work, can you just give our listeners a little information? Do we know anything else about physical activity in other cancer types? Like, beyond colon cancer, is this something that's broad-based across everybody?   Dr. Justin C. Brown: Yeah. So, there is emerging observational evidence that physical activity after diagnosis of early breast cancer, of early prostate cancer, is associated with improved disease outcomes, so disease-free survival, overall survival; that's observational data. We do have randomized clinical trial data on other quality of life endpoints and biologic endpoints in a variety of tumor types. And we know that patients who engage in physical activity or exercise during and after treatment tend to have better quality of life, they have less fatigue, they have improved physical functioning, they have reduced inflammation, improved insulin sensitivity. So, there's a variety of short, medium and potential long-term benefits to being physically active after your diagnosis of cancer. Dr. Westin: Perfect. And how did you end up here? What made you interested in this work? Dr. Justin C. Brown: So, my story dates back all the way to 2002. So, my father died from metastatic colorectal cancer. Dr. Westin: I'm sorry. Dr. Justin C. Brown: No, no, it's okay. I mean, if that didn't happen, I wouldn't be here today. And so, he is with me every day. And, when he asked his physician, "Is there anything I can do to improve my long-term outcome?" This was 2002 before we knew how patient lifestyle factors really improved or impacted disease outcomes. And so, my whole life's mission has been focused on trying to empower cancer survivors, so people from the point of diagnosis on, with information about how the choices they make outside of the oncology clinic have a profound impact on how they feel, function, and survive. And so this has come full circle for me because now I'm able to generate evidence that hopefully will inform clinical practice about how patients who are exactly like my dad and wanted to know what they could do to improve their outcomes, we now have the data that we can provide more precise recommendations about what patients might consider doing to improve their long-term disease outcomes. Dr. Westin: Great. Wow. It's so inspiring, and again, I am sorry for your loss. But I'm glad that you're really transitioning it into positive things. So, let's help everybody understand first just the overall design of the trial that you utilized, the CALGB/SWOG 80702 clinical trial. Dr. Justin C. Brown: Yeah. So this trial was a two-by-two factorial trial, and it randomized patients to three years of Celecoxib; the anti-inflammatory drug, or three years of placebo. And that was the primary analysis. The primary hypothesis was that Celecoxib would improve disease-free survival versus placebo. And that paper was published by my mentor, Jeff Meyerhardt, in JAMA last year. And that analysis showed that Celecoxib did not improve disease-free survival over placebo. The other factor of the two-by-two design was a randomization to three months of FOLFOX therapy, 5- fluorouracil and oxaliplatin, or three months of FOLFOX. And that analysis contributed to an international pooled consortium called the IDEA Consortium. And that analysis was published in 2018 in New England Journal of Medicine, and the follow-up overall survival analysis was published in Lancet Oncology in 2020. And that showed that while overall, three months of FOLFOX was not inferior to six months, there were some lower-risk patients that achieved good disease control with a shorter regimen of chemotherapy. And so, that has changed practice, and now there are certain lower-risk patients that are getting treated with three months of FOLFOX chemotherapy instead of six months. But patients with high-risk features still continue to get six months of therapy. That was the primary questions that that study was designed to answer: the Celecoxib versus placebo and then the contribution to the international pooling project to answer the question of three versus six months of postoperative therapy. Dr. Westin: Well, that's a really clever design. And then I love how you have an additional question built in here. So, why don't you explain how you incorporated your exercise objectives and also what this nested cohort design is? Dr. Justin C. Brown: Yeah. So, this is a unique opportunity to leverage an ongoing clinical trial to conduct an observational study. So, what we did is, about midway through chemotherapy, we asked patients if they wanted to participate in a lifestyle substudy. And if they chose to participate in the lifestyle substudy, they were asked questions about their physical activity and their dietary patterns and how much they weighed. And we measured those things midway through chemotherapy, and then we also measured them again about six months after patients finished their chemotherapy. And so, what this allowed us to do is to leverage all of the amazing resources that were put into place in the randomized clinical trial—that is, a homogenous patient sample, uniform treatments—and systematically ascertain disease outcomes to answer a question in an observational setting—that is, "Does physical activity relate to disease-free survival and overall survival?" So that is the nested cohort within the larger randomized clinical trial. Dr. Westin: Okay, perfect. And then just tell us how you measured the physical activity and the questionnaire that you utilized. Dr. Justin C. Brown: Yeah. So physical activity was measured by a self-reported questionnaire, and the questionnaire is included as a supplement to the JCO paper. So, if people are interested in using this questionnaire, it is available. And it asks 10 different types of physical activities, and it asks the frequency with which those activities are done in the past two months. And using the answers that the patients provided, we were able to calculate which patients were more physically active versus those that were less physically active. And we were also able to understand were the activities that they participated in more vigorous or less vigorous. So, it provided us with a lot of important details regarding the types of physical activities that patients reported during and after chemotherapy. Dr. Westin: Great. That's so interesting. And then, of course, we know diet is important, right? So, you did assess diet as well in this group. You want to give us a little bit of detail on that? Dr. Justin C. Brown: Yeah. So, we measured diet with what's called a Food Frequency Questionnaire, and it asks a series of questions regarding habitual dietary intake. And we know that people who are more physically active tend to be more mindful about what they eat. And so, that's an important confounding variable in trying to understand the relationship between physical activity and disease-free survival. So, we measured diet using that questionnaire. At the same time, we measured physical activity during and after chemotherapy. And that was included in our analysis so that we can attribute the association that we observed to the physical activity per se. Dr. Westin: Okay. And how often did you assess these time points? I'm sorry if I missed it. Dr. Justin C. Brown: So, we measured physical activity and diet two times. We measured it midway through chemotherapy, and then about six months after patients finished their chemotherapy. Because we know that activity, as well as diet, changes from when patients are being actively treated to after they finish their systemic therapy. Dr. Westin: Okay. Perfect. Great. All right, so let's hear it. What were your primary findings? Dr. Justin C. Brown: So, the benefit for the simple messaging is that any activity is better than no activity. That is, if patients need to know the bottom line, my advice is that they find an activity that they like to do and they do it for the rest of their life. For patients who want a little bit more precision, we can think about physical activity on a spectrum of intensity. So the examples I would give a patient is we can do walking, we can do jogging, and we can do running. And jogging is more intense than walking, and running is more intense than jogging. And so, if you decide to do more intense activities, you don't have to do them as much in a week. If you choose to do walking, you need to do more walking than if you choose to do running. And so, this will help to clarify what types of activities are beneficial. So, some people might choose to play tennis, which is a vigorous activity, one day a week. And that would provide them—from our analysis, that provides them with a disease-free survival and overall survival benefit. If a patient says, "My joints are too old and too achy that I can't play tennis, but I can walk around my neighborhood," then we know that those patients may need to do a little bit more activity, maybe a 20 to 30 minutes a day, three to five days a week, in order to achieve a meaningful disease-free survival benefit. So, this helps us to understand with a little bit more precision what we should be advising patients. And if patients say, "I can't do this” or “I prefer to do that," that helps us to have evidence-based recommendations about what is likely to be beneficial and worthwhile to improve their long-term disease outcomes. Dr. Westin: It's so awesome. And I think it's so great to have just very clear guidelines that we can give our patients. I know I've said it already during this podcast, but every time I—because I think we all get so frustrated with these vague recommendations, like, "Okay, drink water, eat healthy." You know, really, I want bullet points of what I can do. Now, we talked a little bit about some of the findings in other cancer types that were already existing. So, can we extrapolate your findings to other cancer types? Dr. Justin C. Brown: I think there is a reasonable expectation that our findings can probably generalize to early-stage breast cancer and maybe to prostate cancer. And the reason I say this is because these are tumor sites where there is existing evidence that being more physically active is associated with improved long-term disease outcomes. Now, the specific magnitude of benefit, I'm not sure if that will generalize. But I do think that this study provides a framework to start thinking about how we can understand the specific characteristics of physical activity that might be more or less important in terms of maximizing long-term disease outcomes. Dr. Westin: That is perfect. So, tell me, what are your next steps with this work? Dr. Justin C. Brown: So, one of the findings that this study reported was that patients who were more physically active during their chemotherapy were more likely to receive more of their planned chemotherapy. They had a higher chemotherapy RDI. So, some of us on this paper have been very fortunate that we received funding from the National Cancer Institute to launch a Bayesian Adaptive Trial of exercise, aerobic exercise, during chemotherapy, and the primary study endpoint is chemotherapy relative dose intensity. So, what we're going to be able to do is to understand, in a randomized clinical trial setting, does different doses of aerobic exercise have a causal effect on improving chemotherapy RDI? Because one of the hypothesized mechanisms through which we think physical activity may improve disease-free survival and overall survival is it enhances a patient's ability to tolerate systemic therapy. And so, we have the funding. We are in the process of planning that study. It should begin later this year, and that will provide us with concrete randomized evidence to understand if exercise during chemotherapy for colon cancer has a causal effect and can improve adherence to systemic therapy. Dr. Westin: That's outstanding. And can our listeners potentially participate in that? Are you looking for sites? Dr. Justin C. Brown: So this study will be launched at Pennington Biomedical Research Center, where I am, in Baton Rouge. This study will also take place at Kaiser Permanente, Northern California, so if there are people on the West Coast listening, as well as at Dana-Farber Cancer Institute in Boston. And so, we are part of a larger consortium of four studies that are trying to understand the benefits of both exercise as well as nutrition and their role in impacting how patients feel, function, and tolerate anti-cancer therapy in a variety of cancer sites. And we are focused on colon cancer, specifically. Dr. Westin: Well, that's great. I hope our listeners will get involved. And those of our listeners that are survivors, you heard some very clear data on what you can do to help impact your overall survival, as well as quality of life. So, I hope you'll implement that. Thank you again so much for being here, Dr. Brown. The time just flew by. And again, for the listeners, this was the JCO manuscript published August 9th, 2022, “Physical Activity in Stage III Colon Cancer: The CALGB/SWOG 80702 Trial.” And until next time, we'll see you at JCO After Hours. Take care.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Dr. John Kirwan is Executive Director of the Pennington Biomedical Research Center and holds the George A. Bray, Jr. Endowed Super Chair in Nutrition.  He also leads the Integrated Physiology and Molecular Metabolism Laboratory at Pennington Biomedical and is the Director/Principal Investigator of the Louisiana Clinical and Translational Science Center.Dr. Kirwan's professional expertise includes over 30 years of research, teaching, and service in the obesity and diabetes fields. He received his clinical physiology training at Washington University School of Medicine in St. Louis, Missouri, his PhD in Human Bioenergetics at Ball State University, Muncie, Indiana, his MSc in Exercise Biochemistry from the University of Massachusetts, Amherst, Massachusetts, and his BA (Hons) from the University of Limerick, Ireland.Among his most important research contributions is the discovery that for a significant number of patients, diabetes can be cured by surgically altering the physiology of the intestine and stomach.   For more information about the work at the Baton Rouge Area Foundation, don't forget to visit braf.org.

The COVID-19 pandemic had a significant impact on the health of patients living with obesity. Two national lockdowns in 18 months saw obesity rates increase. Was it due to the impact on people's mental health? In this episode, Alexander is joined by Professor Donna Ryan, Professor Emeritus at Pennington Biomedical Research Center in Baton Rouge, Louisiana, to answer this question and more. Professor Ryan explores the challenges of ‘long COVID' in relation to obesity, explains why vaccines are crucial in providing protection, and provides counsel to some common misconceptions around COVID and obesity. In our 5th episode of Unlearn to Learn, and as we start to emerge from 2 years of the pandemic, it's time to unlearn everything you thought you know about COVID-19 and its impact on patients living with obesity. Spread the word: Follow, like, share, review We want to build a Unlearn to Learn community. That starts with helping to spread the word about this series. COME AND SAY HELLO: We'd love to see your reviews and feedback – let us know what you think, and any questions you have with #UnlearntoLearn on Twitter. The team @worldobesity will be in touch, do follow us there for more information on Unlearn to Learn. Want to tell us more? You can tell us more or more in-depth feedback here - Unlearn to Learn - What do you think?

We all think we know the basics of weight loss. It is all about consuming fewer calories than you burn. Eat less, move more. Calories in, calories out. But there's much more to it than these simple equations, as a trip to the enormous Pennington Biomedical Research Center in Baton Rouge, Louisiana - a hub of such research - shows. In this episode, we break down the science of why it's so hard to lose weight, and look at what the kinds of stories heralded as a weight-loss success really look like in practice.  See omnystudio.com/listener for privacy information.

In a week chock full of Supreme Court news, justices recently weighed in on the redistricting debate taking hold in Louisiana by putting a temporary hold on the lower court's order requiring a second majority Black congressional district. WRKF's Capital Access Reporter Paul Braun tells us where this latest ruling leaves the redistricting maps. Over in Baton Rouge, the Pennington Biomedical Research Center received a grant to research causes and solutions for cachexia, a debilitating wasting condition responsible for up to 30% of cancer deaths. Professor at the center and one of the researchers on this study, Dr. Steven Heymsfield, joins us for more on cachexia research what they hope to find.  A new in-patient home for children with behavioral health issues has just opened on the Northshore. The recently-completed $10 million dollar “Methodist Children's Home of Southeast Louisiana,” seeks to fill the gap in mental health treatment available for children in the state. CEO of Louisiana United Methodist Children and Family Services, Rick Wheat, shares what he hopes to accomplish with this new home. Today's episode of Louisiana Considered was hosted by Adam Vos. Our managing producer is Alana Schreiber and our digital editor is Katelyn Umholtz. Our engineers are Garrett Pittman, Aubry Procell, and Thomas Walsh.  You can listen to Louisiana Considered Monday through Friday at 12:00 and 7:30 pm. It's available on Spotify, Google Play, and wherever you get your podcasts.  Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to. Louisiana Considered is made possible with support from our listeners. Thank you! See omnystudio.com/listener for privacy information.

We have exciting news: Baby Steps is back with an IVF to give away! We'll gather at Pennington Biomedical Research Center in Baton Rouge on Saturday, November 12, 2022. You can get all the details at babystepsfunrun.com. Registration is open now. We can't wait!

Join LaTangela for another round of #RandomResearch - The surveys went out - the results are in! This week on the #TanLine we are chatting with Dr. Rob Newton, Jr. - Assoc. Professor At Pennington Biomedical Research Center Mark you calendar for the Senior Black American Health Fair 2022 Saturday, May 14th 9a.m.-1p.m. @ Pennington Biomedical - 6400 Perkins Rd. For more details click HERE *********************************************************************************** NEW MUSIC ALERT NEVER KNEW - LaTangela Fay NEW BOOK ALERT P.O.O.F. (Power Over Obstacles Forever) - LaTangela Fay Sherman ************************************************************************************ THE LATANGELA SHOW RADIO - WEMX- Baton Rouge, La. Mon-Fri 10a.m.-3p.m.CST KTCS - Beaumont, Tx. Mon-Fri 10a.m.-3p.m.CST TV - WLFT - Baton Rouge, La. KGLA - New Orleans, La. The Louisiana Film Channel YouTube - #LaTangelaFay Podcast - ALL digital platforms www.LaTangela.comSee omnystudio.com/listener for privacy information.

สรุปงานวิจัย “The energy balance model of obesity: beyond calories in, calories out” Kevin D Hall, I Sadaf Farooqi, Jeffery M Friedman, Samuel Klein, Ruth J F Loos, David J Mangelsdorf, Stephen O'Rahilly, Eric Ravussin, Leanne M Redman, Donna H Ryan, John R Speakman, Deirdre K Tobias ตีพิมพ์ใน : The American Journal of Clinical Nutrition วันที่ตีพิมพ์ : 4 กุมภาพันธ์ 2565

The ALL ME® Podcast Calorie Restricted Diets and Anti-Aging – Dr. Jacob Mey What if you could make a small change that would help you extend your life a little longer? Like, who doesn't want to live longer as I know I want to live forever if I could.   What if cutting your calories by just 10% could add another 5 years to your life? In this podcast we speak with Dr. Jacob Mey from the prestigious Pennington Biomedical Research Center on the impact Calorie Restricted Diets have on slowing down the aging process. We also explore the sustainability of these types of diets and what's in store with future research.                  During our interview we talk about the research that has been conducted on various species such as flies and mice and how that may translate into human data. About Dr. Mey Dr. Mey is an Assistant Professor at Pennington Biomedical Research Center in Baton Rouge, Louisiana and is also a Registered Dietitian. He is an expert in human nutrition and metabolism and uses clinical-translational research approaches to understand the link between diet and health. He trained under an NIH T32 grant on “Botanical Approaches to Combat Metabolic Syndrome,” where he investigated the role of whole-grain dietary intake and botanical components on whole-body and skeletal muscle protein turnover. Dr. Mey's additional research interests include understanding the role of nutrition and metabolism in respiratory health, ketone body metabolism and clinical malnutrition. Although he has a full-time commitment to research, Dr. Mey actively volunteers for dietetic professional practice groups of the Academy of Nutrition and Dietetics. He is particularly passionate about elevating the dietetic profession and encouraging dietitians to engage in research. Resource Links: Twitter: @CakeNutrition Websites: and Email: Follow Us: Twitter: @theTHF Instagram: @theTHF Facebook: Taylor Hooton Foundation #ALLMEPEDFREE Contact Us:  Email:  Phone: 214-449-1990 ALL ME Assembly Programs:

Dr. Eric Ravussin is the Associate Executive Director for Clinical Science at Pennington Biomedical Research Center. Recently, Dr. Ravussin published a study that showed reducing calories by 14 percent over two years generated more T cells, which play a key role in immune function and slow the aging process. On this episode we talk about the specifics within the study and how obesity is impacting the world today and into the future. Follow Jon & Mike below: Jon and Mike on Instagram @curiositywithjonandmike Follow Jon and Mike on Facebook @curiositywithjonandmike

The idea of burning fat by eating more is enticing for many, which can be why keto diets have continued to rise in popularity over the last few years. In this episode of The Good Clean Nutrition Podcast, host Mary Purdy, MS, RDN speaks with Dr. Jacob Mey, a registered dietitian with a PhD in Kinesiology, Nutrition and Rehabilitation Sciences, to discuss the many myths surrounding the ketogenic diet. Tune in as they clarify the origins of the keto diet, debunk common misconceptions, and dive into the potential risks and benefits of attempting this trending diet. Plus, learn sustainable tips from Dr. Mey toward successfully adopting (or continuing to follow) the ketogenic diet. Jacob Mey, PhD, RD is a Registered Dietitian who earned his PhD in Kinesiology, Nutrition and Rehabilitation Sciences from the University of Illinois, at Chicago. He is currently an Associate Professor at Pennington Biomedical Research Center, where his clinical research interests include skeletal muscle metabolism, ketogenesis and clinical malnutrition. In addition to his full-time commitment to research, Dr. Mey actively volunteers for Academy dietetic practice groups and is passionate about elevating the dietetic profession. For show notes, transcripts, and to learn more about host Mary Purdy, MS, RDN, visit http://healthcare.orgain.com/podcast. Disclaimer: This podcast is for informational purposes only and is not intended to be medical advice. The material discussed on this podcast, and displayed on the associated webpage, is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health regimen.

Dr. Katzmarzyk is Professor and Associate Executive Director for Population and Public Health Sciences at the Pennington Biomedical Research Center where he holds the Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes. Dr. Katzmarzyk is an internationally recognized leader in the field of physical activity and obesity, with a special emphasis on pediatrics and ethnic health disparities. He has over two decades of experience in conducting large clinical and population-based studies in children and adults. He has published his research in more than 580 scholarly journals and books, and has delivered over 210 invited lectures in 16 countries. In addition to his research, Dr. Katzmarzyk plays a leading role in national health advocacy initiatives. He chairs the Research Advisory Committee for the U.S. Report Card on Physical Activity for Children and Youth for the National Physical Activity Plan Alliance. He also recently served on the 2018 U.S. Physical Activity Guidelines Advisory Committee for the U.S. Department of Health and Human Services and the World Health Organization Guideline Development Group for the WHO 2020 Guidelines on Physical Activity and Sedentary Behavior in Youth, Adults and Older Adults. In 2019 and 2020, Dr. Katzmarzyk was recognized as a highly cited researcher by the Web of Science. _____________________ This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

We know south Louisiana is famous for its good food and festivals, a vibrant petrochemical sector, and a thriving hospitality sector. Many of us may not realize that Louisiana leads the way in certain healthcare specialties - not just the diabetes and obesity research that goes on at the Pennington Biomedical Research Center, but some really innovative care for very rare diseases. Kevin Tracy is Director of the National Hansen's Disease Program, which is based right here in Baton Rouge and is the epicenter of Hansen's Disease research and information in the United States. Hansen's Disease is better known as Leprosy. Although it's not the biblical plague it once was, it still exists around the world today. Fortunately, a lot more is known about it today than back in biblical times or even in the late 1800s, when south Louisiana was home to one of the country's foremost leprosy hospitals, or leprosaria, in Carville. Today, that center remains open only as a museum, but the Hansen's Disease center is alive and well here in Baton Rouge. Kevin Tracy has been CEO of the center since September of 2019. Prior to that, he worked for the federal government's Center for Medicare and Medicaid Services for nearly a decade. Kevin has a degree in nursing and a graduate degree in accounting with a focus on healthcare administration.  Dr. Jonas Fontenot is Chief Operating Officer of the Mary Bird Perkins Cancer Center, a comprehensive cancer center in Baton Rouge that celebrated its 50th anniversary in late 2021 and recently announced some new partnerships that are reshaping the local cancer care market. Mary Bird Perkins started out as a radiation treatment center – the first in Baton Rouge – and has since expanded to provide a range of service to thousands of patients across the region. Jonas Fontenot is not only a medical doctor, as well as an MD he's also an expert in medical physics, with a Ph.D in medical science.  In addition to helping lead Mary Bird Perkins, he continues to teach and do research and has been the recipient of more than $4M in research grants to support his work around cutting-edge radiation treatments.  As impressive as Jonas's resume is, probably his greatest claim to fame in Baton Rouge is that he helped care for Mike the Tiger No. 6, when the big cat mascot was diagnosed with a rare cancer several years ago.  Out to Lunch is recorded live over lunch at Mansurs on the Boulevard. You can see photos from this show by Erik Otts at our website. And there's more lunch-table conversation about Baton Rouge healthcare at our website itsbatonrouge.la. See omnystudio.com/listener for privacy information.

Dr. Katzmarzyk is Professor and Associate Executive Director for Population and Public Health Sciences at the Pennington Biomedical Research Center where he holds the Marie Edana Corcoran Endowed Chair in Pediatric Obesity and Diabetes. Dr. Katzmarzyk is an internationally recognized leader in the field of physical activity and obesity, with a special emphasis on pediatrics and ethnic health disparities. He has over two decades of experience in conducting large clinical and population-based studies in children and adults. He has published his research in more than 580 scholarly journals and books, and has delivered over 210 invited lectures in 16 countries. In addition to his research, Dr. Katzmarzyk plays a leading role in national health advocacy initiatives. He chairs the Research Advisory Committee for the U.S. Report Card on Physical Activity for Children and Youth for the National Physical Activity Plan Alliance. He also recently served on the 2018 U.S. Physical Activity Guidelines Advisory Committee for the U.S. Department of Health and Human Services and the World Health Organization Guideline Development Group for the WHO 2020 Guidelines on Physical Activity and Sedentary Behavior in Youth, Adults and Older Adults. In 2019 and 2020, Dr. Katzmarzyk was recognized as a highly cited researcher by the Web of Science. _____________________ This podcast episode is sponsored by Fibion Inc. | The New Gold Standard for Sedentary Behaviour and Physical Activity Monitoring Learn more about Fibion: fibion.com/research --- Collect, store and manage SB and PA data easily and remotely - Discover new Fibion SENS Motion: https://sens.fibion.com/

Prof. Leanne Redman is a Professor of Reproductive Endocrinology & Women's Health, based at the Pennington Biomedical Research Center. As the director of the Reproductive Endocrinology and Women's Health Laboratory, she is focused on understanding the intergenerational transmission of obesity. She has published on maternal diet, preeclampsia, and gestational diabetes, amoung other issues. She and her colleagues are currently conducting a rigorous trial to determine the effects of a 6-month gestational intervention with calorie restriction and food provision to promote maternal weight maintenance and fat loss in 100 pregnant women with grades 2 and 3 obesity. Show notes are available at sigmanutrition.com/episode402/ You can support the podcast at patreon.com/sigmanutrition/

Episode 23: I Don't Like Your KETone: Keto Diets or Keto Krazy. Ketones over here, Ketones over there, Ketones and asparagus spears? Ketones are currently everywhere! The Plant-Based Riot welcomes Dr. Jacob Mey, RD, Ph.D., to explore ketone diets in vegans and non-vegans. Dr. Mey is a post-doc fellow with the world-renowned Pennington Biomedical Research Center, where he researches ketones, diet, and disease. It is inevitable, and people simply can't help themselves. If you are on a ketone diet, chances are you have probability annoyed a few friends by continually and publicly profess your undying allegiance to this fad diet. Whether attending social gatherings, visiting your favorite health food store, or interacting on social media, you probably heard about the keto diet and have been tempted by its promises. In fact, the keto diet was the most searched weight loss diet in 2018 & 2019. But is this diet the weight loss solution we've all been waiting for, right? Or is this simply another fad diet that promises more than it can deliver Likewise, the vegan world has also begun to dip its toe in the ketone diet pool. So what gives, should a keto diet be a serious consideration as a viable, long-term diet, or should we send this dies packing with the likes of the Carnivore, Atkin, and the Lectin free diet? Further, what does a vegan keto diet even look like? So Ketones, friend, or a foe? Join us with Dr. Jake Mey, registered dietitian, researcher & nutritionist, as he tells us about the risks and benefits associated with the keto diet. Join Dan and Brian and Dr. Jake Mey as they peek behind this curtain of secrecy and decode the dietary deceptions to arm listeners with more information concerning their diet and health. If you want to contact Dr. Jake Mey, you can find him on the following platforms. 1.https://twitter.com/CakeNutrition 2.https://www.pbrc.edu/research-and-faculty/postdocs/mey-jacob-phd.aspx

Although this is a show about business in New Orleans, once in a while we have to admit there's some pretty interesting things going on an hour or so west of us, in Baton Rouge. There are two impressive institutions in Baton Rouge – not including the legislature. One is the Pennington Biomedical Research Center. It has over 450 employees. They work in 43 laboratories, on a 200-acre campus, focused primarily on researching causes and cures for chronic diseases.  And then there's the LSU Innovation Park. It's an incredibly successful business incubator and technology transfer office. In the last 20 years it has generated $22m and created 134 full time jobs in Baton Rouge. The Associate Executive Director of the Pennington Biomedical Research center is Dave Winwood. The Assistant Executive Director of the LSU Innovation Park, is also Dave Winwood. Christina Womack is a New Orleans native. Christina's business covers New Orleans, the Northshore, Southern Mississippi, and Southern Alabama. Christina employs 10 independent contractors. When you need one of them, they'll show up at your house, or school, in an unmarked vehicle. The reason the vehicle is unmarked is that there is apparently a social stigma involved with Christina's business. And that is, killing lice. Christina's business is called Nitpicking in NOLA. Christina founded it in 2009. And, although people might be reluctant to admit they use it, business is booming. Generally on Out to Lunch we pair guests whose businesses have something in common. It's hard to imagine any business having much in common with removing lice, and it's equally hard to match the groundbreaking work going on at Pennington. Strangely, Dave Winwood and Christina Womack make for great lunchtime conversationalists. Photos over lunch at Commander's Palace by Jill Lafleur are at our website. And here's more lunchtime conversation about New Orleans bio innovation. See omnystudio.com/listener for privacy information.

Obesity is a nationwide problem, but we seem to run into it more frequently in Louisiana. Fortunately, we have a world renowned resource in the Pennington Biomedical Research Center in our backyard. Carey sat down with a pivotal player at that resource, Dr. Steven Heymsfield to talk about the growing epidemic.

Bob Nolan from the Pennington Biomedical Research Center sat down with Carey to talk about what they've got going on.

For this week's Feature Discussion, join author author Hannah Valantine and Senior Associate Editor Biykem Bozkurt as they discuss the Original Research Article "Cell-Free DNA to Detect Heart Allograft Acute Rejection." TRANSCRIPT BELOW Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal editors. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well, Carolyn, I think we've got an interesting feature this week. Dr. Carolyn Lam: Oh boy, we sure do. This one is one of those potentially practice changing landmark papers. I'll give you a clue. It's about using cell-free DNA to detect heart allograft acute rejection in transplantation. Huge, huge, but you got to wait. Listen to the summaries of this week's exciting issue first. Greg, you want to go first? Dr. Greg Hundley: Yes. And I can't wait for that feature discussion. I think that's going to be one of our top papers this year, but first onto some of the summaries. So my first article comes to us from Dr. Pilar Alcaide from Tufts University School of Medicine. So Carolyn, despite the well-established association between T-cell mediated inflammation and non ischemic heart failure, the specific mechanisms triggering T-cell activation during the progression of heart failure and the antigens involved are poorly understood. So Carolyn, these authors hypothesize that myocardial oxidative stress induces the formation of isolevuglandin modified proteins that function as cardiac neoantigens to elicit CD4 positive T-cell receptor activation, and then promote heart failure. Dr. Carolyn Lam: Oh, that's really interesting. Inflammation in heart failure is a hot topic. Tell me more. Dr. Greg Hundley: So Carolyn, these authors discovered that TCR antigen recognition increases in the left ventricle as cardiac dysfunction progresses, and they identified a limited repertoire of activated CD4 positive T-cell chronotypes in the left ventricle. Mechanistically, cardiac pressure overload resulted in reactive oxygen species dependent dendritic cell accumulation of isolevuglandin protein adducts, which induced robust CD4 positive T-cell proliferation. Dr. Greg Hundley: So collectively, Carolyn, these results demonstrate an important role of reactive oxygen species induced formation of isolevuglandin modify cardiac neoantigens that lead to TCR dependent CD4 positive T-cell activation within the heart. And therefore, these results help understand the relationship between T-cell mediated inflammation and heart failure. Dr. Carolyn Lam: Wow. Super. Thanks, Greg. I'm moving all the way from basic science now to talk about intensive lifestyle interventions, which we know are first line approaches to effectively treat obesity and manage the associated cardio-metabolic risk factors. However, to date, whether effective lifestyle based obesity treatment in primary care works, we need more data. And this is what this paper provides. Dr. Carolyn Lam: This comes from Dr. Katzmarzyk and colleagues from Pennington Biomedical Research Center in Los Angeles. And what they report is the PROPEL Trial, which randomly allocated 18 clinics equally to usual care or an intensive lifestyle intervention, and subsequently enrolled 803 adults with obesity from participating clinics. The usual care group continued to receive their normal primary care, while the intensive lifestyle intervention group received 24 months of high intensity lifestyle-based obesity treatment in a program, embedded in the clinic setting and delivered by health coaches in weekly sessions initially and monthly sessions from months seven through 24. Dr. Greg Hundley: Well, Carolyn, sounds like a really practical study here. So what were these results? Dr. Carolyn Lam: Yes, Greg, this was a pragmatic trial. And although pragmatic, this lifestyle intervention was consistent with national guidelines, and participants receiving the PROPEL intensive lifestyle intervention lost significantly more weight over 24 months than those receiving usual care. Results also demonstrated clinically relevant improvements in high density lipoprotein cholesterol, total to HDL cholesterol ratio, metabolic syndrome severity, and fasting glucose. The PROPEL model may therefore be a viable option to deliver effective obesity and cardio-metabolic risk factor treatment in primary care. Dr. Greg Hundley: Well, Carolyn, what an interesting article. A lot that we can take home from that. Well, I'm going to switch and talk to you about blood flow restoration and its effect on venous thrombosis and vein wall injury. And this article comes to us from Dr. Farouc Jaffer from the Massachusetts General Hospital at Harvard Medical School. So Carolyn, up to 50% of patients with proximal DVT will develop the post-thrombotic syndrome, which is characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. While catheter based interventions, enabling restoration of blood flow, have demonstrated little benefit on post-thrombotic syndrome, the impact on the acuity of the thrombus and mechanisms underlying this finding remain obscure. So here, these authors in experimental and studies, they examined whether restoration of blood flow has a restricted time window for improving DVT resolution. Dr. Carolyn Lam: Oh, very interesting, and potentially a significant clinical implications, huh? Tell us about it. Dr. Greg Hundley: Well, Carolyn, there were two types of studies performed in mice and those in human subjects in the ATTRACT pharmacomechanical Catheter-Directed Thrombosis trial. So in the series of experiments in mice, within a restricted therapeutic window, restoration of blood flow improved DVT resolution. And then in the human studies, the pharmacomechanical catheter directed thrombolysis did not improve the PTS scores for patients having a symptom onset to randomization or SOR time of less than four days or greater than eight days. So therefore, further studies are warranted to examine the value of time restricted restoration of blood flow strategies to reduce post-thrombotic syndrome in patients with deep venous thrombosis. Dr. Carolyn Lam: Interesting. Thanks. Greg. My next paper is related, also talking about anticoagulants. And this time, the authors led by Dr. Hijazi from Uppsala Clinical Research Center in Sweden evaluated the risk benefit balance of antithrombotic therapy according to kidney function in the AUGUSTUS Trial. As a reminder, in the AUGUSTUS Trial resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, whereas aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or PCI treated with a P2Y12 inhibitor. Dr. Greg Hundley: Carolyn, thanks for reviewing for us the AUGUSTUS Trial results. So what did they find in this study? Dr. Carolyn Lam: So what they did is they looked at patients with atrial fibrillation and ACS and/or a PCI, and found that apixaban, as compared to vitamin K antagonists, displayed a consistent safety and efficacy profile, irrespective of kidney function, without significant interaction and in accordance with the overall trial. Dr. Carolyn Lam: Next, they found that aspirin, relative to placebo, on top of oral anticoagulation and a P2Y12 inhibitor resulted in more bleeding, irrespective of kidney function again, and with an even greater increase among those with a GFR more than 80. Dr. Carolyn Lam: These findings can help clinicians perhaps make informed decisions on the antithrombotic therapy in patients with atrial fibrillation and kidney disfunction, with ACS and/or a PCI. Dr. Greg Hundley: Very nice. Dr. Carolyn Lam: All right, Greg. Well, tell you what, let's go onto the other papers in this issue. I would like to tell you about a letter to the editor from Dr. Saleh on carotid atherosclerosis thickness, a proxy for cardiovascular disease events. There's an ECG challenge by Dr. Liu entitled, intriguingly, A Noteworthy Electrocardiogram, and this really describes new SD segment elevation and its differential diagnosis. To refresh, look up the paper. Dr. Greg Hundley: Very nice, Carolyn. Well, I have a research letter to tell you about from Dr. Lanz entitled One Year Outcomes of a Randomized Trial, Comparing a Self-expanding to a Balloon Expandable Transcatheter Aortic Valve. And then finally, Dr. Maron has a very nice perspective piece entitled Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy Mavacamten in Perspective. Well, Carolyn, I can't wait to get to this week's feature discussion. How about you lead us through that? Dr. Carolyn Lam: Me too. Let's go, let's go. I could not be more thrilled to be doing today's feature discussion. And I have to admit I'm feeling very star struck because I'm with two of the women I think are most at my own respect. And the first is Dr. Hannah Valantine, and she is professor from Stanford University now and also at NIH, and she's the corresponding author of today's incredible paper. And the next guest is of course, Dr. Biykem Bozkurt, senior associate editor of circulation from Baylor College of Medicine. Dr. Carolyn Lam: Welcome, ladies. On the topic today, it's really landmark. We could be talking about a new gold standard that may replace the endocardial myocardial biopsy. Wow. So if I could just start off, Dr. Valantine, could you please tell us about your study? What is cell-free DNA? Dr. Hannah Valantine: Yes. Thank you. It's a wonderful opportunity to be doing this podcast, and thank you for the interest on the technology. If you can imagine, when you put an organ transplant, essentially what you're doing is a genome transplant. You're transferring the genome of the donor into the recipient. Dr. Hannah Valantine: Now, we all have single nucleotide polymorphisms, otherwise known as SNPs, that are unique to the donor DNA, and that are unique to the recipient DNA. So that once we put that organ in and there is a teeny little bit of damage, little fragments of DNA come out of the donor organ into the recipient circulation, and we can pick that up, circulating in the plasma. And that's why we call it donor derived cell-free DNA. Dr. Hannah Valantine: So, you know the SNPs that belong to the donor, and you know the SNPs that belong to the recipient. You extract the DNA from the plasma of the recipient and you sequence it. And bingo, you can tell what the percentage of that cell-free DNA is coming from the donor, and that is the basis of the test. Dr. Carolyn Lam: Oh my goodness. I love that explanation. It's so lucid, and it's reminding me of what happened when I was pregnant. It's the same technology that's used, I think, in prenatal testing, in oncology in some cases, but this is the first time that you've shown it in a multicenter approach in cardiac transplantations. So could you please tell us about that? Dr. Hannah Valantine: Yes. Well, we first did this work in a single center when I was at Stanford, where we developed the technology, myself and a couple of colleagues in bio-engineering. But when you do a study, as you know, in one center, doesn't mean it's necessarily transferable or trans label into multicenter. Dr. Hannah Valantine: So when I went off to NIH, I transferred the technology there and did something else that was rather unique. I put together a consortium of the five local heart and lung transplant centers in the DC area. And we enrolled patients from each of those five centers into this study. And in the heart cohort, which is what is reported here, we were able to take blood samples on a serial basis. And there were 171 of them in the study. So, what happens is that we genotype the donor and the recipient of each of those 170 patients at the beginning, before the transplants, so that we could then know and monitor their cell-free DNA as they progress at serial time points after the transplant. And that's the way we were able to confirm the value of this test. Dr. Hannah Valantine: I can describe to you what the findings were. So what we found is that the cell-free DNA started to rise a lot earlier, before the heart biopsy showed a rejection. So it was just remarkable, because of the serial samples, we were able to look back and say, well, was there an elevation of the cell-free DNA before the positive biopsy? And that was definitively the case. Dr. Hannah Valantine: As you know, there are two types of rejection, antibody, mediated, rejection, and cellular driven rejection. And antibody mediator rejection, quite frankly, is the Achilles heel of organ transplantation because it's difficult to pick up and it occurs, that means it's diagnosed late, and it's really resistant to treat. Dr. Hannah Valantine: So what we found in this study is that the cell-free DNA was elevated for at least a couple of months before the heart biopsy actually showed the presence of antibody mediated rejection. And that has significant implications for the management of patients. And there are some other characteristics of the cell-free DNA that distinguish cellular and antibody mediated rejection. That is really important because the two types of rejection are treated differently. That's a great excitement of the results of this study. Dr. Carolyn Lam: Oh my gosh. I'm just tingling. My hairs are standing, just listening to you explain that. I really think we have a true liquid biopsy now for cardiac transplant rejection. Dr. Carolyn Lam: But Dr. Bozkurt, you're such an expert in heart transplantation. Could you frame it for us, just how significant these findings are? Dr. Biykem Bozkurt: This is transformative. So first, I would like to congratulate Dr. Valantine and her team for pioneering and leading this concept for such a long time. And now with this validations study, for providing the framework for the future studies for alternative strategies, implementation of how we're going to do this, as the liquid biopsy in lieu of endomyocardial biopsy. Dr. Biykem Bozkurt: So the findings that I think are truly practice changing are, yes, this study validates the ability to detect rejection. The second very interesting finding is predict the rejection almost three months before that we're able to detect it by histopathology. Third, for the first time, being able to detect antibody mediated rejection, as well as cellular. Fourth, being able to eliminate the necessity in approximately 81% of the patients with a very high negative predictive value. Dr. Biykem Bozkurt: Now, but I'm going to pose this question to Hannah. What is the gold standard now? Because in the historical past, we used to rely on histopathology to be diagnosed myocardial infarction. Now, we know that Troponin-I is a driver or Troponin-T or cardiac troponin. The profile of this is so, I would say, impressive, both for its negative predictive value. And I do realize the sensitivity and specificity is over 80%. And in the positive predictive, when we use the biopsy as the gold standard, the numbers are not as high as a negative predictive value, but if we add the clinical, those who've had the LV dysfunction, those who developed rejection subsequently, three months later, it is performing quite well. Dr. Biykem Bozkurt: So what now is going to be the gold standard? I'm thinking, shall we start calling things allograft injury and go and embrace the injury drum  now with this profiling, and then trying to determine whether we can intervene early and prevent rejection? And I guess my question is, what's the next step? Dr. Hannah Valantine: Thank you for that lovely summary. This clearly, at this point, I would say the gold standard should be the cell-free DNA because in the study we switched it on its head. And we said, if the cell-free DNA is the gold standard, then how sensitive is the heart biopsy? And it wasn't very sensitive. And this is something that we've known for many years. Dr. Hannah Valantine: And I'll tell you a little anecdote that has driven my passion over the last 35 years to come up with a better diagnostic tool. When I was first an assistant professor and using echocardiography to study whether or not we could replace the biopsy, I had a patient who in whom I noticed had diastolic dysfunction. And my protocol was if we saw diastolic dysfunction, we actually did a biopsy. And to cut a long story short, I ordered these biopsies, and the biopsy was negative. And in retrospect, I think he had antibody mediated rejection. But the sad part of it is that after a few weeks I got a call from his wife to inform me that she found him dead in bed. Dr. Hannah Valantine: And so this has really motivated me to really find something better. And to your question, the cell-free DNA should be the gold standard. The problem is that physicians are human, and there is often takes a lot of time for adoption. So even though the data speaks for itself, that adoption piece is a social, psychological factor that to be overcome. But actually, we've had a really interesting experience in the context of COVID-19 when we were not able to do elective procedures, many centers have reverted to the cell-free DNA technology, and guess what? The patients are doing very well, as we documented in this study. So I think we're going to see a huge paradigm shift in the management of patients with cell-free DNA being the gold standard. Dr. Hannah Valantine: But I think that's not all because you asked the very important question about what's next and what's next about this research is to figure out, using the same technologies, why it is that black patients reject their organs so much more than white patients. And in this study, I hope you noticed that 44% of the cohort are African-American. And so it opens the door now to study this area. And then the third implication is that we can use cell-free DNA to actually look at other mechanisms and develop the technology. For example, DNA methylation profiles will come on board very shortly that can teach us more about where the damage is happening and add to the diagnostic tools. Dr. Biykem Bozkurt: I have another burning question. The peripheral gene expression profiles that also are available clinically to be able to characterize these patients. How do you see the difference in the cell-free DNA versus gene expression? And in this study, both the donors and the recipients were genotyped. Do you see the necessity of having to do so? Whether the current, you know, snip analysis will allow us not having to genotype patients, which may have an implication on the cost, as well as the practicality of how to implement this on the clinician bedside. Dr. Hannah Valantine: Absolutely. As you know, there are now several ways to get around having to genotype the donor by using an array of 260 or so SNPs known that are common in the population. And you can use that. And when you use that technology, it's equally sensitive. So that is what is going to move this forward in terms of clinical utility, so that we don't have to do that. So it's an extension of the technology. I like to do the recipient and donor genotyping because there's so much more research. So from the research perspective, it's useful to continue this technology. But for the application, yes, we're going to be able to do it without the genotyping, and rapidly. Dr. Hannah Valantine: And even beyond that, there are now new technologies coming up that we could use. For example, DVPCR, that could be translated into more rapid, an even more rapid test. Right now, the test takes about a day and a half to come back. My goal ultimately would be to have a point of contact test that we could actually use right there to make the diagnosis on a sample of the patient's plasma. So lots of new things coming out. This is just the beginning. Dr. Biykem Bozkurt: We're also excited about the possibility of the cell-free DNA, being able to predict coronary artery vasculopathy and/or other clinical events. So I'm sure your team is going to come up with results in regards to the future prognostication regarding the clinical events. So any, perhaps, prediction as to what we shall see those who don't decay, especially after 28 days? I'm very intrigued by those patients, which I think was a subgroup in your study. Dr. Hannah Valantine: Yeah. So that's absolutely right. What we are seeing is that those in whom the cell-free DNA remains relatively elevated, because what we find is that immediately after transplant, in the first 24 hours, the cell-free DNA diminishes and to a baseline low level. And then when there is rejection, we see these spikes, but when it's remains elevated, this might be a predictor of ongoing injury, an injury to the vascular dithulium that then sets up the familio for allograft vascular disease. And so we're chasing that hypothesis. The trouble is that the end point takes a while to develop, which is good for the patients. And so look out for future studies that where we will look at the correlation of the cell-free DNA as a predictor of allograft vasculopathy. Dr. Hannah Valantine: The other really interesting thing goes back to mechanism. You mentioned the question of consistently elevated cell-free DNA. And so I'm asking myself the question, whether this three floating cell-free DNA can actually act as a trigger of the immune response and therefore lead to damage and rejection. And that again is research that's ongoing, which will have significant implications for patient care. And it might actually help us in understanding why it is that African-American patients reject their organs. Because even those that are doing well in this study, they had relatively higher levels of cell-free DNA throughout the course, and did not decay as in the same pattern as the white patients. So lots of exciting work to come. Dr. Carolyn Lam: Oh my goodness, this is just a mind blowing discussion. So might not just be a marker, but even a target for rejection or anti-rejection therapy. And as a trialist, I'm already thinking ahead. Might we see future trials with raised cell-free DNA, but no evidence of rejection on biopsy, and whether or not treating these patients would actually improve outcomes? Dr. Carolyn Lam: So this is incredible. I wish we had all day to chat, and I think I really cannot let this end without at least saying something about Dr. Valantine, your work in diversity, and to just thank you on behalf of everybody for really forging this, and especially as part of Circulation. As you know, we have an issue focused on disparities, and we're just incredibly privileged to have you on the podcast today. Biykem, please would you add some last words? Dr. Biykem Bozkurt: I second those sentiments. We're grateful to Dr. Valantine for being a trailblazer for our transplant patients, for our community, to enhance the diversity, and for scientific excellence in all fronts. So thank you, Dr. Valantine. Dr. Hannah Valantine: Thank you very much. I'm humbled by your comments and very appreciative, and thank you for the support of this work. Dr. Carolyn Lam: Thank you, audience, for listening today. You've been listening to Circulation on the Run. Thank you for joining us, and don't forget to join us again next week. Dr. Greg Hundley: This program is copyright of the American Heart Association 2021.

There is some amazing, groundbreaking work being don in Baton Rouge on a daily basis. Carey sat down with some of the doctors responsible for that work.

This episode is a discussion with Dr. James Dorling who is at the Pennington Biomedical Research Center in Baton Rouge, Louisiana. He along with co-authors from Pennington, Tufts University, Duke University and Washington University in Saint Louise provided a review on the effects of caloric restriction on human physiological, psychological, and behavioral outcomes with a special focus on results from the CALORIE Phase 2 study, a randomized control trial to determine the effect of reducing caloric intake by 20% on various markers of aging. We will discuss these key finding and what is next for us to learn about caloric restriction.

Dr. Jake Mey is a registered dietitan and a human nutrition researcher. He is a Postdoctoral Research Fellow at the Pennington Biomedical Research Center. His work focuses on diet, muscle & metabolism. Dr. Mey has a PhD in human nutrition and kinesology. Show notes: sigmanutrition.com/episode370

Although we're living in an age of hyperbole where headlines and politicians are apt to cast everything in terms of absolute disaster or unprecedented achievement, it might be surprising but no exaggeration to claim that there are institutions and scientists in Baton Rouge that are world leaders in healthcare. Dr. John Kirwan is Executive Director of the Pennington Biomedical Research Center. “Pennington” as it is mostly referred to locally, is a 30-year-old facility in Baton Rouge that is arguably the most prestigious research institute in the world focused on chronic diseases diabetes and obesity. Recently Pennington has become home to a bariatric treatment center that is expected to attract the most severely obese patients from around the world. Dr. Kirwan came to Pennington in 2017 from the famed Cleveland Clinic, where he was working on a cure for type II diabetes. When he came here he brought a couple of dozen researchers with him, along with their millions in federal research dollars, making John Kirwan his own Baton Rouge mini economic development engine. Dr. Barbara Griffith is Chief Executive Officer of Woman's Hospital in Baton Rouge. The hospital is one of the largest birthing centers in the world, delivering more than 8-thousand babies a year, as well as providing a host of other healthcare services to women and babies. Dr Griffith started out as an emergency medicine doctor with 20 years clinical experience. She had only been in the position of CEO of Woman's Hospital when she was met the emergency nobody saw coming: the global coronavirus pandemic. Healthcare has been a hot topic for years, decades, probably forever, but at no time in recent memory has it become more important than in this era of COVID-19, as we as a state, nation and planet try to navigate a pandemic that has upended every aspect of our lives and society, and especially our healthcare system. It's extraordinary how work being done in Baton Rouge is so central to the path of healthcare worldwide. You can see photos from this show by Jill Lafleur at our website. And check out more lunchtime conversation about the changing world Baton Rouge healthcare. See omnystudio.com/listener for privacy information.

Although we're living in an age of hyperbole where headlines and politicians are apt to cast everything in terms of absolute disaster or unprecedented achievement, it might be surprising but no exaggeration to claim that there are institutions and scientists in Baton Rouge that are world leaders in healthcare. Dr. John Kirwan is Executive Director of the Pennington Biomedical Research Center. "Pennington" as it is mostly referred to locally, is a 30-year-old facility in Baton Rouge that is arguably the most prestigious research institute in the world focused on chronic diseases diabetes and obesity. Recently Pennington has become home to a bariatric treatment center that is expected to attract the most severely obese patients from around the world. Dr. Kirwan came to Pennington in 2017 from the famed Cleveland Clinic, where he was working on a cure for type II diabetes. When he came here he brought a couple of dozen researchers with him, along with their millions in federal research dollars, making John Kirwan his own Baton Rouge mini economic development engine. Dr. Barbara Griffith is Chief Executive Officer of Woman's Hospital in Baton Rouge. The hospital is one of the largest birthing centers in the world, delivering more than 8-thousand babies a year, as well as providing a host of other healthcare services to women and babies. Dr Griffith started out as an emergency medicine doctor with 20 years clinical experience. She had only been in the position of CEO of Woman's Hospital when she was met the emergency nobody saw coming: the global coronavirus pandemic. Healthcare has been a hot topic for years, decades, probably forever, but at no time in recent memory has it become more important than in this era of COVID-19, as we as a state, nation and planet try to navigate a pandemic that has upended every aspect of our lives and society, and especially our healthcare system. It's extraordinary how work being done in Baton Rouge is so central to the path of healthcare worldwide. See photos from this show on our website. And check out more lunchtime conversation about the changing world Baton Rouge healthcare. See omnystudio.com/listener for privacy information.

Carey celebrates his 100th episode with three remarkable doctors from The Pennington Biomedical Research Center.

Weighing the evidence from clinical trials and faulty belief systems in obesity control, errors in self-reporting of energy balance, dynamic model for predicting obesity, machine learning to predict injuries in combat training, the Vitruvian Man (Woman), and how many steps per day to stay fit. Prof. Diana Thomas is a professor of mathematical sciences at the United States Military Academy at West Point. She holds joint research appointments at Columbia University, Obesity Research Center, and the Pennington Biomedical Research Center and serves on the editorial board for the European Journal of Clinical Nutrition, PloS One, and Nutrition and Diabetes. She has published over 140 peer-reviewed articles in exercise, fitness, nutrition, and body weight regulation. --- Send in a voice message: https://anchor.fm/scientificsense/message Support this podcast: https://anchor.fm/scientificsense/support

In the Covid-19 world, those individuals, especially older males, with comorbidities, like hypertension and diabetes, are at increased risk to complications, if this SARS 2 disease is contracted.The journal Cell Metabolism reported in June of 2018 that early time restricted feeding (eTRE)–between 8 am and 2 pm–increases insulin sensitivity and lowers blood pressure–even in the absence of weight loss, in prediabetic men.Intermittent fasting (IF), which alternates periods of eating and fasting, has been speculated to improve cardiometabolic health more than conventional dieting. Yet, most of the IF evidence, to date, in humans has suggested that the benefits accrue mostly from weight loss.The study authors, from the Pennington Biomedical Research Center in Baton Rouge, Columbia State University, the American Diabetes Association, and the University of Alabama, state that there was a, “need to determine whether the benefits of interventions, such as IF, are mediated only through weight loss or through mechanisms that are independent of weight loss.”These investigators used a “proof-of-concept trial”—using a form of IF called time-restricted feeding (TRF)—to determine whether IF had benefits independent of weight loss.TRF, note the Pennington team, “is a type of IF that extends the daily fasting period between dinner and breakfast the following morning, and, unlike most forms of IF, it can be practiced either with or without reducing calorie intake and losing weight.”TRF is limiting daily food intake to a window of ten hours or less—with fasting the remaining 14 hours, over a 24-hour period. The typical American eats over a 12-hour window (8am to 8 pm on average).The researcher's study period spanned five weeks, in which a group of prediabetic men adopted an (eTRF) schedule—over a six-hour period–versus a second control group of male prediabetics, who adhered to a twelve-hour eating window.The participants consumed only food provided by study staff, were fed enough food to maintain their weight, and ate all meals, while being monitored by study staff.From a metabolic, medical standpoint, glucose tolerance, postprandial (after a meal) insulin, and insulin sensitivity, as measured using a 3-hr oral glucose tolerance test (OGTT) were assessed, while the secondary endpoints were cardiovascular risk factors and markers of inflammation and oxidative stress.It was determined that, “5 weeks of (eTRF) improved insulin levels, insulin sensitivity, beta cell responsiveness, blood pressure, and oxidative stress levels in men with prediabetes—even though food intake was matched to the control arm and no weight loss occurred.”Before you embark on such an eating schedule, be sure to check with your primary care physician to see how such a plan might impact your health profile.

Based on research—Calorie Restriction and Aging in Humans—which appeared online in June of 2020 in the Annual Review of Nutrition—“over the past century, the average life span in higher- and lower-income countries has increased by 15 and 30 years, respectively.”Additionally, “this (outcome) is the result of lessening mortality and morbidity from food shortage, malnutrition, and infectious diseases through improved food supply and quality, as well as, advances in health care.”Aging, which is associated with a decline in an individual’s physical and physiological capabilities, is part of life—as in death and taxes.The speed and progression of age can be effected by such variables, as excess food consumption—overweight and obesity, poor fitness—less than 150 minutes of light to moderate weekly exercise, 75 minutes of moderate to vigorous weekly exercise, or a combination of both, or, the extent of an individual’s exposure to disease—all equaling secondary aging, added to or subtracted from (with prevention in place) the normal primary aging process.According to the Annual Nutrition Reviews researchers from Pennington Biomedical Research Center, Louisiana State University, and Nutrition and Movement Sciences at Maastricht University in the Netherlands, “advanced age is associated with increased mortality and susceptibility to disease. This increase is caused by a progressive decline in physiological function. The slope of this decline over time can be defined as aging,” which, under an optimal scenario, may approach 120 years.Primary aging, note the researchers, “describes the inevitable age-associated decline in physiological and physical functions due to energy expenditure and oxidative stress.” It appears that individuals with higher metabolic rates have shorter life spans—known as the rate-of-living theory—which the Pennington and Maastricht researchers say is, “still a matter of discussion, and may only apply in species, and not between species.”It was also noted that average lifespan is reduced to 61 to 83 years—“an acceleration of this process reflects the interaction between innate aging and the extrinsic influences of the environment.”As aging applies to our functional capacity, I’ve often commented to many of my athlete clients—when my patience (with age) wears thin—discussing my strategic plan—that age is mandatory, but maturity is optional.They’ve also heard me explain from day one that my objective is to make them perform better than before—with a higher quality of health in the years extending beyond their playing career.I recognize three ages—chronological age, what we’re given at birth, performance age, how successful we are at achieving our mental and physical objectives on and off the playing field, and health age, resistance to the effects of chronic fatigue and disease.With the exception of our chronological age, being the constant, the goal from a health age perspective is to work toward a compressed morbidity, pushing illness to the shortest period of time late in life—which is extended toward a higher quality.The pillars of life extension—slowing the aging process—has to do with lengthening the telomeres—segments of DNA occurring at the ends of the chromosomes in eukaryotic cells (that containing a clearly defined nucleus), according to Britannica.com.Read more at MackieShilstone.com

In our 68th episode, Carey talked with Dr. John Kirwan, Executive Director of Pennington Biomedical Research Center, about their current work. They also spoke about health problems our society is facing. Carey also discussed talent acquisition with Dr. Kirwan and how he put his team together.

S2E6 Lots of customers discover Red Stick Spice Company after being given the directive to reduce salt consumption. What better place than our shop to reduce salt without losing flavor? We also hear talk of the DASH Diet—a little bit “Baton Rouge famous” due to research and development at Pennington Biomedical Research Center. To learn more, we’re joined by Renee Puyau, Registered Dietician at Pennington. Renee explains how DASH was originally developed for hypertension, but also supports other health benefits, too. Since DASH is fruit and veggie heavy, Renee gives lots of tips for how to get more servings into each day. (Friendly reminder: this episode is for informational purposes only and is not a substitute for medical advice.) Cooking Segment: Host and Owner of Red Stick Spice Company Anne Milneck takes what she learns from Renee into the Test Kitchen to make a flavorful chicken cutlet using Zahtar. The salt is scant but the taste is plentiful due to Zahtar’s distinct zing—sumac, sesame seeds, and citrus zest come together for a bright flavor that will keep you from missing the salt. The Zahtar chicken is topped with a lush green parsley salad (get those veggies in!) making for a DASH-friendly, quick to prepare dinner. Mentioned on the show: - RECIPE: Make your own Zahtar Chicken with Parsley Salad for dinner tonight! Quick, delicious, DASH friendly - Find out more about the DASH Diet on the Pennington Biomedical Research Center website - Zahtar is where it’s at for flavorful chicken or a bit of Middle Eastern flair for a variety of dishes - We offer an abundance of salt-free spice blends to choose from. Anne gave a shout-out to our Red Bean Seasoning and Gumbo Seasoning. Also give a look to our Smoked Porcini, Shallot & Mustard - Salt Free blend. Don’t forget the Alleppo Pepper! - Cameron came in with our Red Stick Spice Company Oregano Olive Oil to bump up the flavor - If you have a loved one who is watching their salt intake, we offer a Salt Free Zone gift box that would make a delicious and helpful present - Join us for our Not My Mother’s Chicken cooking class!  This Milk Street Partner Location class highlights cooking skills as well as inspiring recipes. Zahtar Chicken with Parsley Salad is on the menu! - Use discount code SMIDGEN15 to save 15% your entire order at Red Stick Spice Co. Did we win you over with Zahtar? Did you already know about DASH? We want to know! Tell us about it on Facebook, Instagram, or Twitter. Hear all Smidgen episodes on Apple Podcasts, Spotify, Google Podcasts, Pandora, or your browser, or your favorite podcast app.  Smidgen is the podcast of Red Stick Spice Co.

As the new year approaches, many people (epidemiologists included!) will resolve to begin exercising more. Making a renewed commitment to exercise is among the most common New Year’s resolutions. Although almost everyone knows they should be exercising, there is a lot of confusion about how much exercise we really need to stay healthy. Does the amount or type of exercise you need depend on whether you’re exercising to lose weight or exercising to stay healthy? Should you be adding a fitness tracker to your gift list? Are you ever ‘too old’ to lift weights? In this episode, new host Bryan James is joined by Hailey Banack to explore these, and other, interesting topics with physical activity expert Dr. Peter Katzmarzyk of the Pennington Biomedical Research Center.

In the August 2019 issue of the Journal of the National Cancer Institute, Justin C. Brown, Director of the Cancer Metabolism Program at LSU’s Pennington Biomedical Research Center and colleagues report that, “for colorectal cancer patients, new research shows a clearer connection than previously known between fat deposits in certain areas of the body and higher rates of death from all causes within seven years of cancer diagnosis.”

We talk a lot about the importance of getting in shape especially at the beginning of a new year or before hitting the beach but do you know what it really means to be in shape And how, exactly, do we get healthy It s a question local businesses and entrepreneurs are helping their clients better understand using new technologies, and new approaches to fitness. Tiffany Stewart is a clinical psychologist and the director of the Behavioral Technology Lab at the Pennington Biomedical Research Center. Tifffany s work focuses on breaking the illusion that looking healthy which is to say skinny or sexy is not the same thing as being healthy. In her work Tiffany uses technology apps and games that she has helped develop that aim to improve health and performance. Hayden Clark is owner of Irontribe Fitness, a local boutique health club that focuses on getting its clients healthy through 45 minute high intensity, group workouts, paired with one on one style coaching. Irontribe is a Birmingham based company with some 50 franchise owned studios around the country. Hayden opened Baton Rouge s first Irontribe in 2017 and has seen its membership grow as customers today are increasingly turning to boutique health clubs over traditional all purpose gyms to get in shape. Photos over lunch at Mansurs On The Boulevard. See omnystudio.com/listener for privacy information.

Thirty years ago, a young, high energy entrepreneur left his private sector job to create the Louisiana Business and Technology Center on the LSU campus, a business incubator for small startups. In the three decades since, the LBTC has helped launch hundreds of businesses and has spawned the creation of the much larger LSU Innovation Park, a 13 year old facility on its own south campus dedicated to research commercialization. This edition of Out to Lunch Baton Rouge is a special tribute to that man, Charlie D Agostino, who is retiring at the end of the 2018. Few people in Louisiana know more about business incubation and economic development than Charlie, who himself is a 1972 LSU graduate with degrees in chemistry in business. He started his career with NASA. In 1988, LSU recruited him to develop the LBTC, which today is the flagship entity on the 200 acre Innovation Park, which is about five miles downriver from the main LSU campus and today includes not only the LBTC but also the LSU Student Incubator, LSU Ag Center Food Incubator, Pennington Biotech Initiative, ProtoStripes Center, and the Louisiana Emerging Technology Center. It s an incredible ecosystem that really seeks to connect the dots in a market that hasn t typically been an easy place for entrepreneurs and small businesses to get a start. Charlie, thanks for being here today on Out to Lunch. Joining host Stephanie Riegel and Charlie is the man who will succeed him, Dave Winwood. Currently Dave divides his time between LSU s Innovation Park, where he is Assistant eEecutive Director, and the Pennington Biomedical Research Center, where he serves as Associate Executive Director. Photos over lunch at Mansurs on the Boulevard. See omnystudio.com/listener for privacy information.

One positive thing we can say about social media is, it s a great leveler. Even CEO s and celebrities reveal that, although their giant homes and incomes may be far removed from ours, their daily lives and fears are not that different. Nonetheless, even in a world with no secrets, you d probably still be surprised if a celebrity went on Instagram with photos of their kid s head lice. Christina Womack says there is still a social stigma against admitting you re infested with lice. And Christina ought to know she s the owner of Nitpicking in NOLA, a company that will come to your home or school and get rid of nits. On the whole other end of the spectrum of human science, there s Dave Winwood. Dave is a serious over achiever who is visiting Out to Lunch from from Baton Rouge where he s Associate Director of Pennington Biomedical Research Center as well as Assistant Executive Director of LSU s Innovation Park. Pennington Biomedical Research Center has over 450 employees. They work in 43 laboratories, on a 200 acre campus, focused primarily on researching causes and cures for chronic diseases. Innovation Park is an incredibly successful business incubator and technology transfer office. In the last 20 years it has generated 22m and created 134 full time jobs in Baton Rouge. In New Orleans we re familiar with conversation about finding ways for business and the arts to come together. We re less familiar with the relationship between business and science. Or business and head lice. Photos over lunch at Commander s Palace by Jill Lafleur. See omnystudio.com/listener for privacy information.

Jake is a registered dietitan and a human nutrition researcher. His work focuses on diet, muscle & metabolism. He is a Postdoctoral Research Fellow in Integrated Physiology and Molecular Medicine at the Pennington Biomedical Research Center. He is also a contractor in Inflammation and Immunity research at the renowned Cleveland Clinic. In This Episode We Discuss Understanding evidence-based research Can sugar, without caloric excess, still have detrimental health effects? Cleveland Clinic study: effect of wholegrains vs. refined grains on glucose metabolism How much sugar counts as a ‘high intake’? At what intakes we see issues Insulin resistance, AGEs and other issues Sigma Nutrition Radio LIVE! - Event in Dublin: sigmanutrition.com/snr-live/

What’s the best way to eat and the right way to exercise to ensure a healthy lifespan? Our guest today is Dr. Stephen Anton, a psychologist who has spent his career researching how lifestyle factors can influence not only obesity, but also cardiovascular disease and other metabolic conditions. Steve is an associate professor and the chief of the Clinical Research Division in the Department of Aging and Geriatric Research at the University of Florida. In today’s episode, we talk to Steve about his work in developing lifestyle interventions designed to modify people’s eating and exercise behaviors in an effort to improve their healthspan and lifespan. One of Steve’s best-known papers appeared in the Obesity Journal titled “Flipping the Metabolic Switch.” The study looked at intermittent fasting and suggested that the metabolic switch into ketosis represents an evolutionary conserved trigger point that has the potential to improve body composition in overweight individuals. Topics we cover in today’s interview include: The increasing prevalence of metabolic syndrome associated with aging. Why so many hospital health and wellness programs fail. How fasting and intermittent energy restriction promote autophagy. The relationship between muscle quality, body fat and health. How age-related loss of muscle function and mass leads to sarcopenia. Effects, risks and benefits of testosterone supplementation in older men. Optimal exercise methods for long-term health. Therapeutic approaches that potentially can help avert systemic inflammation associated with aging. Steve’s study that looked at the effects of popular diets on weight loss. Controversies surrounded calorie restriction as a strategy to enhance longevity. Show notes: 2:30: Steve talks about growing up in Tampa and playing sports as a kid. 3:53: Dawn asks Steve about his decision to attend Florida State after high school. 4:17: Dawn comments on how Steve bounced between medicine, business, and psychology before finally deciding to major in psychology. She asks if having two parents who were also psychologists played a role in his decision. 5:24: Ken asks about Steven’s experience pursuing his Ph.D. at the University of Florida. 6:28: Dawn brings up that Steve became a fellow of behavioral medicine at the Pennington Biomedical Research Center in Baton Rouge, La. She mentions that Pennington has one of the nation’s premier programs in obesity metabolism and diabetes. She asks if that was the reason he decided on Pennington. 9:33: Dawn asks what prompted Steve to return to the University of Florida. 10:08: Ken asks what is driving the increased prevalence of metabolic syndrome that’s associated with advanced age. 11:19: Dawn brings up how hospitals have tried to promote health and wellness programs for decades, but notes how hospitals are designed to treat people who are sick and injured rather than delivering lifestyle interventions. She asks if Steve can give a summary of what he has learned in looking at ways to deliver interventions. 13:23: Dawn mentions that the traditional treatment and management approaches for type 2 diabetes are relatively ineffective and only reverse the disease in about one percent of the cases. 15:02: Ken mentions that Jeff Volek, STEM-Talk Guest on episode 43, has been a pioneer in researching type 2 diabetes. 16:49: Dawn points out that she and Ken had an in-depth conversation with Dr. Mark Matson about autophagy on episode seven of STEM-Talk. Matson also discussed fasting, and intermittent energy restriction and how it promotes autophagy, which is often described as the body’s innate recycling system. Dawn asks if Steve can elaborate a little on this process. 18:02: Dawn mentions that Steve has written about muscle quality and body composition and the risk of metabolic diseases and functional decline. She asks about the relationship between muscle quality,

An experienced senior executive with several years of experience in the pharmaceutical and biotechnology industry, Will has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever-changing role of medical affairs at most major medical affairs conferences and is currently president and CEO of the ACMA, whose primary mission is to create industry standards and goals for medical affairs professionals. Will has held key management roles across the industry within medical affairs, such as at Eisai, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim, and Merck. Will previously also served as vice president of medical and scientific affairs at CME LLC, a leading provider of continuing medical education to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva Systems and often provides medical affairs consultancy services for Bain, McKinsey, BCG, Atheneum Partners, and Alpha Insights. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity, where he has collaborated with some of the nation's top research institutions, such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Will was most recently invited to speak at the Center for Medical Technology Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, health care policy makers, physicians, and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among prediabetic overweight and obese individuals. In 2008, Will published a book entitled The Rise of Chemistry: Implications for Industry and Education. He has also held several academic appointments at Seton Hall University's School of Health and Medical Sciences; New Jersey City University; Kean University's College of Natural, Applied, and Health Sciences; and Touro Colleges of Osteopathic Medicine, Pharmacy, and Physical Therapy teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology, and epidemiology. Will has served as a board member for the MSL Institute. He is a member of several organizations, including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), the Drug Information Association (DIA), and the American Chemical Society (ACS). 00:00 Will's background and how he became president and CEO of the ACMA. 02:30 The difference between a sales rep and a medical science liaison (MSL). 04:35 The need for better education among medical affairs and pharma workers. 09:10 Working with key thought leaders and the Consensus Statement they are currently working on. 12:00 How accreditation courses work to help MSLs provide more of a balanced view of a pharma product. 15:50 The pressure for Pharma and manufacturers to become Outcomes Companies. 16:25 How are MSLs evolving? 17:20 “Really, what is the value of the product?” 22:00 How ACMA remains unbiased in their course curriculum. 23:15 How health care providers can verify that they are getting the clearest unbiased pharma information possible from their MSLs. 25:25 EP187 with Sandra Leal and Todd Eury, EP181 with Dr. Lipi Roy. 25:40 The state of opioid addiction in America and how pharma information contributed to the problem. 30:05 EP148 and AEE2 with Jennifer Miller. 30:25 “It's time there's a third party that's vetting what we're doing.” 32:40 You can learn more at medicalaffairsspecialist.org.

Breaking Down the BCMAS Certification: A Conversation with Dr. William Soliman of ACMA An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is currently the President of the Accreditation Council for Medical Affairs (ACMA). Dr. Soliman is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has also held a variety of critical management roles across the industry at Eisai, Veeva, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro College of Physical Therapy & Pharmacy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D, MPHil. from Columbia University, his Bachelor's degree from New York University and a Master's Degree from St. Peter's University focused in Biochemistry & Education. He also completed post-doctoral work at Harvard University T.H. Chan School of Public Health.  William Soliman, PhD, MPhil, MA https://www.linkedin.com/in/williamsoliman1/ ACMA: https://www.medicalaffairsspecialist.org/board-certified-medical-affairs-specialist-program/ wasoliman1@gmail.com This podcast was sponsored by the ACMA. Other Pharmacy Podcast Episodes mentioned in this podcast: Breaking into the pharmaceutical industry as an MSL:   https://html5-player.libsyn.com/embed/episode/id/5508336/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/   What is a Medical Science Liaison (MSL)?   http://html5-player.libsyn.com/embed/episode/id/4974092/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/no-cache/true/   Certifications for pharmacists and Healthcare Professionals:   http://html5-player.libsyn.com/embed/episode/id/5007759/height/360/width/640/theme/standard/autonext/no/thumbnail/yes/autoplay/no/preload/no/no_addthis/no/direction/backward/no-cache/true/ See omnystudio.com/listener for privacy information.

More than a decade ago, researchers at the Pennington Biomedical Research Center in Baton Rouge began recruiting young, healthy Louisianans to voluntarily go hungry for two years. In addition to cutting their daily calories by 25 percent, the dozens who enrolled also agreed to a weekly battery of tests; blood draws, bone scans, swallowing a pill that measures internal body temperature.

Authors: MAJ Aaron P. Crombie, PhD, RD; LTC; LesLee K. Funderburk, PhD, RD; Tracey J. Smith, PhD, RD; Susan M. McGraw; Leila A. Walker, MS; Catherine M. Champagne, PhD, RD, LDN, FADA; H. Raymond Allen, PhD; Lee M. Margolis, MS, RD; Holly L. McClung, MS, RD; Andrew J. Young, PhD. Interview: Researchers discuss a new study conducted by the US Army and the Pennington Biomedical Research Center that shows the effectiveness of waging war against the obesity epidemic in military cafeterias by making small, but effective changes to promote healthy eating and food selection. Their results can be easily applied to civilian settings. DOI: 10.1016/j.jand.2013.01.005.

Dr. Tim Allerton (email: timallerton [at] gmail [dot] com or tweet) is a postdoctoral fellow for the National Institute of Health and Pennington Biomedical Research Center conducting research on metabolic resiliency. He was recently named a National Scholar for the American Kinesiology Association and is also an experienced trainer with over 10 years of experience working with clients and corporations. Tim is the founder of HIT Lab, inc – a metabolic testing and consulting service. This is Tim's second appearance on Corporate Warrior. In Part 1 we discussed the effectiveness of HIT and HIIT for fat loss and metabolic flexibility. To listen to Part 1 - click here. In this episode (Part 2) we discuss: More on Damage Control from The 4-Hour Body and how it works Tim's dislikes of the typical HIT paradigm How Tim started HIT LAB and expanded the business And much more. This episode is brought to you by Hituni.com, providers of the best online courses in high intensity training that come highly recommended by Dr. Doug McGuff and Discover Strength CEO, Luke Carlson. Course contributors include world-class exercise experts like Drew Baye, Ellington Darden and Skyler Tanner. There are courses for both trainers and trainees. So even if you’re not a trainer but someone who practices HIT, this course can help you figure out how to improve your progress and get best results. Check out Hituni.com, add the course you want to your shopping cart and enter the coupon code ‘CW10’ to get 10% off your purchase! This episode is brought to you by VitalExercise.com, a one-of-kind personal training facility in the UK owned and run by world class personal trainer, Ted Harrison. For over 30 years, Ted has been very successful in helping people achieve great results, and, if you’ve seen the blog posts for his episodes on this podcast, you’ve seen that he walks the walk. For 56, he looks amazing! Operating from a HIT base, Ted uses an eclectic mix of training styles to optimise results for his clients. Ted put me through one of the best workouts of my life and is someone I go to for advice often. To book a free consultation either at his facility in Essex in the UK or to find out more about his virtual coaching, which includes personalised training, nutritional and motivational advice, go here where you can fill in a contact form or phone Ted directly for more info. To subscribe via email and get my FREE eBook with 6 podcast transcripts with guests like Dr Doug McGuff, Drew Baye and Skyler Tanner – Click here  

Dr. Tim Allerton (email: timallerton [at] gmail [dot] com) is a postdoctoral fellow for the National Institute of Health and Pennington Biomedical Research Center conducting research on metabolic resiliency. Tim earned his bachelor degree in Kinesiology from Louisiana State University thereafter he earned his master’s degree in in clinical exercise physiology from Northeastern University in Boston, MA. Tim earned his PhD in Exercise Physiology from LSU where his research focused on metabolic flexibility in response to acute bouts of exercise. He was recently named a National Scholar for the American Kinesiology Association and is also an experienced trainer with over 10 years of experience working with clients and corporations. Tim is the founder of HIT Lab, inc - a metabolic testing and consulting service. We cover: The effect that HIT/HIIT has on metabolic flexibility and fat loss The benefits of HIT over and above strength and muscle hypertrophy How to increase the rate of fat loss And much more! This episode is brought to you by Hituni.com, providers of the best online courses in high intensity training that come highly recommended by Dr. Doug McGuff and Discover Strength CEO, Luke Carlson. Course contributors include world-class exercise experts like Drew Baye, Ellington Darden and Skyler Tanner. There are courses for both trainers and trainees. So even if you’re not a trainer but someone who practices HIT, this course can help you figure out how to improve your progress and get best results. Check out Hituni.com, add the course you want to your shopping cart and enter the coupon code ‘CW10’ to get 10% off your purchase! This episode is brought to you by VitalExercise.com, a one-of-kind personal training facility in the UK owned and run by world class personal trainer, Ted Harrison. For over 30 years, Ted has been very successful in helping people achieve great results, and, if you’ve seen the blog posts for his episodes on this podcast, you've seen that he walks the walk. For 56, he looks amazing! Operating from a HIT base, Ted uses an eclectic mix of training styles to optimise results for his clients. Ted put me through one of the best workouts of my life and is someone I go to for advice often. To book a free consultation either at his facility in Essex in the UK or to find out more about his virtual coaching, which includes personalised training, nutritional and motivational advice, go here where you can fill in a contact form or phone Ted directly for more info. For my FREE eBook with 6 podcast transcripts with guests like Dr Doug McGuff, Drew Baye and Skyler Tanner – Click here  

ACMA Board Certified Medical Affairs Specialist Program (BCMAS) Certification – Q&A with Dr. William Soliman - Chair – Accreditation Council for Medical Affairs   An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry. He is currently the Chair of the Accreditation Council for Medical Affairs (ACMA). Dr. Soliman is often invited to speak at important pharmaceutical industry conferences focusing on medical affairs, patient navigation and its relationship to field based medical teams, and the ever-changing role of the medical science liaison (MSL). He has also held a variety of critical management roles across the industry at Eisai, Veeva, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim and Merck. Dr. Soliman previously also served as Vice President of Medical and Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro College of Physical Therapy & Pharmacy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology and epidemiology. Dr. Soliman earned his Ph.D, MPHil. from Columbia University, his Bachelor's degree from New York University and a Master's Degree from St. Peter's University focused in Biochemistry & Education. He also completed post-doctoral work at Harvard University T.H. Chan School of Public Health.  William Soliman, PhD, MPhil, MA https://www.linkedin.com/in/williamsoliman1/ ACMA: https://www.medicalaffairsspecialist.org/board-certified-medical-affairs-specialist-program/ wasoliman1@gmail.com Anne Leighty – P4 pharmacy major: https://www.linkedin.com/in/anneleighty/ This podcast was sponsored by the ACMA. See omnystudio.com/listener for privacy information.

1re heure : Le privé sur la Lune – Reportage de Marie-France Bélanger ; Les carnets insolites du prof Durand - Les mythes déboulonnés ; Les bébés lynx du Biodôme – Reportage de Marie-France Bélanger ; Transgenres et identité – Reportage de Marianne Désautels-Marissal ; Doc / Post-doc - Les retardateurs de flammes avec Annie Chalifour ; La règle de 3 - Grandeur et horreur des volcans, troisième partie. 2e heure : Matière condensée ; La science olympique – L'impact du sport sur le corps avec Claude Bouchard, directeur du Pennington Biomedical Research Center de l'Université de la Louisiane ; Le courrier des Années lumière - Reportage de Renaud Manuguerra-Gagné ; L'identité au scalpel – Entrevue avec l'auteure et sociologue Anne Gotman.

Could something as insignificant as the tiny blueberry offer powerful protection and healing for your body? It can—and probably in ways that you've never dreamed possible. Rich in manganese, phytonutrients, fiber and vitamin C, blueberries are one of the most powerful antioxidants in the plant kingdom. They offer extraordinary anti-inflammatory and anti-cancer properties. They may even help combat diabetes. This was first discovered way back in 1927, when it was found that taking a specific extract of blueberry can significantly slash blood sugar levels. These findings were largely ignored by mainstream medicine. The editorial board on the Journal of the American Medical Association—America's most revered medical journal—argued that this had to be impossible. They claimed that such extracts could never be standardized. Now, thanks to investigations by independent Life Extension scientists, you can buy an inexpensive, specific blueberry extract, further enhanced with pomegranate, which works wonders. In 2005, researchers discovered that the polyphenols which a specific blueberry extract contains can reverse both motor defects and cognitive defects which can develop as your body ages. Polyphenols are natural plant molecules with potent antioxidant capabilities. According to the Pennington Biomedical Research Center, it is the multi-leveled range of polyphenols that brings blueberries their anti-cancer, anti-inflammatory and antioxidant properties. The two most active constituents found in blueberries are anthocyanins and pterostilbene. Blueberry anthocyanins are considered one of nature's most potent antioxidants. It's pterostilbene, the other blueberry constituent, that helps maintain healthy lipid and glucose levels within healthy ranges. Through its unique biological effects and antioxidative potential, pterostilbene also helps maintain your healthy DNA structure. Blueberry extract also triggers neurogenesis—by stimulating nerve supply and adaptability in the part of the brain primarily affected by Alzheimer's disease—the hippocampus. People who take in a lot of natural polyphenol molecules from plants have significantly lower rates of neurodegenerative disorders. Blueberry polyphenol molecules are able to cross the blood brain barrier. They've even been shown to enhance the release of essential neurotransmitters from aged brain cells. Meanwhile in 2008, animal-based research carried out at University of Florida discovered blueberry extract can prevent the final steps in the formation of destructive amyloid-beta proteins—a major trigger for loss of memory and good brain functions. Other recent studies show that blueberry extract may prevent DNA damage and encourage fast, accurate DNA repair. A recent animal study showed that blueberry compounds increased mean lifespan by 28%. Translate that into human terms and you're looking at 22 years. Finally, and most fascinating to me, is the way natural compounds in blueberries can act as nootropics. These are often known as smart drugs, neuro enhancers, or cognitive enhancers, which improve aspects of mental functions. I not only have a love of organic blueberries and eat a lot of them when they're in season. I have been so impressed with the new Life Extension Blueberry Extract with Pomegranate that I take it daily. Do see if you benefit from it as much as I have—and let me know, won't you? Life Extension, Blueberry Extract with Pomegranate, http://www.iherb.com/life-extension-blueberry-extract-with-pomegranate-60-veggie-caps/37818?rcode=yes026

Could something as insignificant as the tiny blueberry offer powerful protection and healing for your body? It can—and probably in ways that you’ve never dreamed possible. Rich in manganese, phytonutrients, fiber and vitamin C, blueberries are one of the most powerful antioxidants in the plant kingdom. They offer extraordinary anti-inflammatory and anti-cancer properties. They may even help combat diabetes. This was first discovered way back in 1927, when it was found that taking a specific extract of blueberry can significantly slash blood sugar levels. These findings were largely ignored by mainstream medicine. The editorial board on the Journal of the American Medical Association—America’s most revered medical journal—argued that this had to be impossible. They claimed that such extracts could never be standardized. Now, thanks to investigations by independent Life Extension scientists, you can buy an inexpensive, specific blueberry extract, further enhanced with pomegranate, which works wonders. Blueberries are not bilberries. It’s important that you know the difference. Both berries belong to the Heath family of plants, which include rhododendron, American laurel, and broom. The difference between them comes in the size of their seeds, and their skin. Bilberries have been grown all over northern Europe since the 16th century. Unlike blueberries, bilberries are acidic in flavor. These dark blueish-purple berries have long been popular in Sweden. Blueberries (their botanical name is Vaccinium corymbosum or Vaccinium angustifolium) tend to be hybrids of three native American species. They are up to four times larger than bilberries, and they’re pleasingly sweet. Most commercially cultivated blueberries are grown in North America and New Zealand, as well as to some degree in parts of Western Europe. When researchers analyzed vegetables and fruits to determine their antioxidant capacities, blueberries came high on the list. They can destroy free radicals, combat oxidative stress, help maintain healthy blood flow, healthy LDL and blood pressure levels. Blueberry extract, when combined with other natural berry components, may even help prevent and clear bladder infections by blocking bacteria from attaching to the walls of the bladder. In 2005, researchers discovered that the polyphenols which a specific blueberry extract contains can reverse both motor defects and cognitive defects which can develop as your body ages. Polyphenols are natural plant molecules with potent antioxidant capabilities. According to the Pennington Biomedical Research Center, it is the multi-leveled range of polyphenols that brings blueberries their anti-cancer, anti-inflammatory and antioxidant properties. The two most active constituents found in blueberries are anthocyanins and pterostilbene. Blueberry anthocyanins are considered one of nature’s most potent antioxidants. It’s pterostilbene, the other blueberry constituent, that helps maintain healthy lipid and glucose levels within healthy ranges. Through its unique biological effects and antioxidative potential, pterostilbene also helps maintain your healthy DNA structure. Blueberry extract also triggers neurogenesis—by stimulating nerve supply and adaptability in the part of the brain primarily affected by Alzheimer’s disease—the hippocampus. People who take in a lot of natural polyphenol molecules from plants have significantly lower rates of neurodegenerative disorders. Blueberry polyphenol molecules are able to cross the blood brain barrier. They’ve even been shown to enhance the release of essential neurotransmitters from aged brain cells. Meanwhile in 2008, animal-based research carried out at University of Florida discovered blueberry extract can prevent the final steps in the formation of destructive amyloid-beta proteins—a major trigger for loss of memory and good brain functions. Other recent studies show that blueberry extract may prevent DNA damage and encourage fast, accurate DNA repair. A recent animal study showed that blueberry compounds increased mean lifespan by 28%. Translate that into human terms and you’re looking at 22 years. Finally, and most fascinating to me, is the way natural compounds in blueberries can act as nootropics. These are often known as smart drugs, neuro enhancers, or cognitive enhancers, which improve aspects of mental functions. I not only have a love of organic blueberries and eat a lot of them when they’re in season. I have been so impressed with the new Life Extension Blueberry Extract with Pomegranate that I take it daily. Do see if you benefit from it as much as I have—and let me know, won’t you? Life Extension, Blueberry Extract with Pomegranate, 60 Veggie Caps http://www.iherb.com/life-extension-blueberry-extract-with-pomegranate-60-veggie-caps/37818?rcode=yes026

Could something as insignificant as the tiny blueberry offer powerful protection and healing for your body? It can—and probably in ways that you’ve never dreamed possible. Rich in manganese, phytonutrients, fiber and vitamin C, blueberries are one of the most powerful antioxidants in the plant kingdom. They offer extraordinary anti-inflammatory and anti-cancer properties. They may even help combat diabetes. This was first discovered way back in 1927, when it was found that taking a specific extract of blueberry can significantly slash blood sugar levels. These findings were largely ignored by mainstream medicine. The editorial board on the Journal of the American Medical Association—America’s most revered medical journal—argued that this had to be impossible. They claimed that such extracts could never be standardized. Now, thanks to investigations by independent Life Extension scientists, you can buy an inexpensive, specific blueberry extract, further enhanced with pomegranate, which works wonders. Blueberries are not bilberries. It’s important that you know the difference. Both berries belong to the Heath family of plants, which include rhododendron, American laurel, and broom. The difference between them comes in the size of their seeds, and their skin. Bilberries have been grown all over northern Europe since the 16th century. Unlike blueberries, bilberries are acidic in flavor. These dark blueish-purple berries have long been popular in Sweden. Blueberries (their botanical name is Vaccinium corymbosum or Vaccinium angustifolium) tend to be hybrids of three native American species. They are up to four times larger than bilberries, and they’re pleasingly sweet. Most commercially cultivated blueberries are grown in North America and New Zealand, as well as to some degree in parts of Western Europe. When researchers analyzed vegetables and fruits to determine their antioxidant capacities, blueberries came high on the list. They can destroy free radicals, combat oxidative stress, help maintain healthy blood flow, healthy LDL and blood pressure levels. Blueberry extract, when combined with other natural berry components, may even help prevent and clear bladder infections by blocking bacteria from attaching to the walls of the bladder. In 2005, researchers discovered that the polyphenols which a specific blueberry extract contains can reverse both motor defects and cognitive defects which can develop as your body ages. Polyphenols are natural plant molecules with potent antioxidant capabilities. According to the Pennington Biomedical Research Center, it is the multi-leveled range of polyphenols that brings blueberries their anti-cancer, anti-inflammatory and antioxidant properties. The two most active constituents found in blueberries are anthocyanins and pterostilbene. Blueberry anthocyanins are considered one of nature’s most potent antioxidants. It’s pterostilbene, the other blueberry constituent, that helps maintain healthy lipid and glucose levels within healthy ranges. Through its unique biological effects and antioxidative potential, pterostilbene also helps maintain your healthy DNA structure. Blueberry extract also triggers neurogenesis—by stimulating nerve supply and adaptability in the part of the brain primarily affected by Alzheimer’s disease—the hippocampus. People who take in a lot of natural polyphenol molecules from plants have significantly lower rates of neurodegenerative disorders. Blueberry polyphenol molecules are able to cross the blood brain barrier. They’ve even been shown to enhance the release of essential neurotransmitters from aged brain cells. Meanwhile in 2008, animal-based research carried out at University of Florida discovered blueberry extract can prevent the final steps in the formation of destructive amyloid-beta proteins—a major trigger for loss of memory and good brain functions. Other recent studies show that blueberry extract may prevent DNA damage and encourage fast, accurate DNA repair. A recent animal study showed that blueberry compounds increased mean lifespan by 28%. Translate that into human terms and you’re looking at 22 years. Finally, and most fascinating to me, is the way natural compounds in blueberries can act as nootropics. These are often known as smart drugs, neuro enhancers, or cognitive enhancers, which improve aspects of mental functions. I not only have a love of organic blueberries and eat a lot of them when they’re in season. I have been so impressed with the new Life Extension Blueberry Extract with Pomegranate that I take it daily. Do see if you benefit from it as much as I have—and let me know, won’t you? Life Extension, Blueberry Extract with Pomegranate, 60 Veggie Caps http://www.iherb.com/life-extension-blueberry-extract-with-pomegranate-60-veggie-caps/37818?rcode=yes026

Episode 92: Dr. Eric Ravussin of the Pennington Biomedical Research Center is on the show to discuss their recent human trials on the effects of caloric restriction on longevity markers, fasting, hormesis and obesity.

Host: John J. Russell, MD Dr. John Russell speaks with Dr. Donna Ryan, Professor Emeritus at Pennington Biomedical Research Center in Baton Rouge Louisiana. Dr. Ryan serves as co-Chair of the panel to revise the NIH-supported evidence-based Guidelines on the Evaluation and Management of Overweight and Obesity in Adults. She is past President of The Obesity Society and currently Associate Editor in Chief of the journal, Obesity.

Chad and Brenda Walding join me on today’s podcast to explain how sitting can be one of the most harmful things you do each day. You’ve probably seen the headlines… “Sitting is the New Smoking” “7 Ways Sitting Will Kill You” “Sitting is Taking Years Off Your Life” …and you may have hoped it was media hype. Sitting is Worse Than Donuts… It isn’t hype. More and more studies have come out proving how bad sitting is EVEN if you work out regularly. Here are three important studies about sitting… Study One: Sitting causes premature death (especially in women!) Alpa Patel (PhD), an epidemiologist at the American Cancer Society, tracked the health of 123,000 Americans between 1992 and 2006. The men in the study who spent six hours or more per day of their leisure time sitting had an overall death rate that was 20 percent higher than the men who sat for three hours or less. The death rate for women who sat for more than six hours a day was about 40 percent higher. Study Two: Daily Exercise Doesn’t Reduce The Threat Of Sitting Marc Hamilton, Ph.D, Professor, and inactivity researcher at the Pennington Biomedical Research Center, has published 12 studies on the topic of sitting. Each one has proven how dangerous modern sitting is. Here is a summary statement on why typical exercise isn’t a solution… “People don’t need the experts to tell them that sitting around too much could give them a sore back or a spare tire. The conventional wisdom, though, is that if you watch your diet and get aerobic exercise at least a few times a week, you’ll effectively offset your sedentary time…this advice makes scarcely more sense than the notion that you could counter a pack-a-day smoking habit by jogging. Exercise is not a perfect antidote for sitting. Sitting is hazardous. It’s dangerous.” — Marc Hamilton Study Three: Sitting increases risk of mortality, cardiovascular disease, type 2 diabetes, metabolic syndrome risk factors, and obesity. In an extensive study (2007 Nov;56 (11):2655-67. Epub 2007 Sep 7) the evidence concluded that sitting was a “…potentially major clinical and public health significance…the dire concern for the future may rest with growing numbers of people unaware of the potential insidious dangers of sitting too much.” (Emphasis Added) Scary huh? If you’re like most people, sitting isn’t really something you can just stop doing. But here is the good news…you don’t have to. Today’s podcast guests, Chad and Brenda (Doctors of Physical Therapy) have spent years behind the scenes working on a solution for their patients. It combines the positive studies of Activity Thermogenesis and their expertise in Physical Therapy to gently reverse the negative impact of sitting inside your body…and it works even if you HAVE to sit all day! They are sharing their solutions on this podcast episode and I know you’ll learn a lot from them. Resources We Mention Standing desk (this is the one I use)

Host: Alan S. Brown, MD, FNLA Host Dr. Alan Brown welcomes Dr. Marc Hamilton, Professor at Pennington Biomedical Research Center in Baton Rouge, LA. Their convesation focuses on the cardiometabolic consequences of lengthy sitting times, such as in people with "desk job careers."

Timothy Church, M.D. of Pennington Biomedical Research Center

Have you ever had an experience like this: You and a friend start jogging together. Neither of you have been exercising much, but after a few days, your friend is easily striding along as you wheeze, gasp and hold onto your aching side. Do not feel bad about your performance; it may be your genes.Scientists have identified about 200 genes that play a role in our body's ability to become fitter, referred to as "adaptation to exercise." In this episode, we talk to Mark Olfert of the University of California at San Diego and Claude Bouchard of the Pennington Biomedical Research Center. They have organized a symposium on the genetics of adaptation to exercise, to take place at the Experimental Biology conference in New Orleans in April. They will give us a flavor for the research in this field by telling us a bit about their own work. (Begins at 3:51)In the Buzz in Physiology (Begins at 1:21) University of Illinois researchers are developing a program to train people to avoid falls. This research could be particularly valuable for the elderly, for whom falling can be an especially dangerous proposition. And a study from the University College London Medical School sheds light on why patients with cirrhosis may have a more regular heart rhythm than is normal, and why they develop hepatic encephalopathy, a neurological disorder. The body's inflammatory response may be the common thread behind the development of these conditions. 

Guest: Timothy Church, MD, PhD Host: Bruce Japsen Motivating your patients to exercise can be a challenge. But Dr. Timothy Church of the Pennington Biomedical Research Center in Baton Rouge, Louisiana, tells host Bruce Japsen that even 15 minutes a day can help, citing research that shows even minimal exercise can be a benefit to the obesity epidemic and other diabetes risk factors.

Guest: Timothy Church, MD, PhD Host: Bruce Japsen Motivating your patients to exercise can be a challenge. But Dr. Timothy Church of the Pennington Biomedical Research Center in Baton Rouge, Louisiana, tells host Bruce Japsen that even 15 minutes a day can help, citing research that shows even minimal exercise can be a benefit to the obesity epidemic and other diabetes risk factors.